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ABSTRACT
Mutations in HIV-1 Vpr Affect Pathogenesis in T-Lymphocytes and Novel Strategies to Contain the
Current COVID-19 Pandemic
Antonio Solis Leal
Department of Microbiology and Molecular Biology, BYU
Doctor of Philosophy
HIV-1 Vpr: Acquired immunodeficiency syndrome (AIDS) is caused when HIV depletes CD4+
helper T cell levels in infected patients. Distinct AIDS development rates have shown that there are Rapid
Progressor (RP) and Long-Term Non-Progressor (LTNP) patients, but the circumstances governing these
differences in the kinetics of helper T cell depletion are poorly understood. Mutations in the Viral Protein
R (Vpr) gene have been suggested to have a direct impact on helper T cell depletion. Interactions of Vpr
with both host and viral factors affect cellular activities such as cell cycle progression and apoptosis. The
Vpr mutants R36W and R77Q have been associated with RP and LTNP phenotypes, respectively;
however, these findings are still controversial. This study examines the effects that Vpr mutations have in
the context of HIV-1 infection of the HUT78 T cell line, using replication-competent CXCR4-tropic virus
strains. Our results show a replication enhancement of the R36W mutant accompanied by increased
cytotoxicity. Interestingly, the R77Q mutant showed a unique enhancement of apoptosis (measured by
Annexin V and TUNEL staining) and G2 cell cycle arrest; these effects were not seen with WT, R36W,
or Vpr null viruses. Thus, point mutations in Vpr can exhibit profound differences in mechanisms and
rates of cell killing. The vpr gene is thought to be an important virulence factor in Human
Immunodeficiency Virus type 1 (HIV-1). Vpr polymorphisms have been associated with different rates of
AIDS progression. However, there is controversy about the cytopathic and virulence phenotypes of Vpr
mutants, with contradictory conclusions about the same mutants. Here, we examine the replication
capacity, apoptotic induction, and G2 cell cycle arrest phenotypes of three vpr mutants compared to wildtype HIV-1. One mutant associated with rapid AIDS progression replicated more efficiently and killed
cells more rapidly than wild-type HIV-1. Another mutant associated with slow AIDS progression
triggered apoptosis more efficiently than wild-type HIV-1 and showed significant levels of G2 cell cycle
arrest. These results shed additional light on the role of vpr polymorphisms in T cell killing by HIV-1 and
may help to explain the role of Vpr in different rates of AIDS progression.
SARS-CoV-2: SARS-CoV-2 is an enveloped virus responsible for the current global pandemic,
COVID-19. Because this virus is novel, little is known about its sensitivity to disinfection. In this study,
suspension tests against SARS-CoV-2 were performed using three commercially available quaternary
ammonium compound (quat) disinfectants and one laboratory-made 0.2% benzalkonium chloride
solution. Three of the four formulations completely inactivated the virus after 15 seconds, even in the
presence of a soil load or when diluted in hard water. Thus, it seems that quats inactivate SARS-CoV-2
relatively rapidly, making them potentially useful for controlling SARS-CoV-2 spread in the community.
Keywords: HIV-1, Vpr, SARS-CoV-2, Benzalkonium Chloride.
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CHAPTER 1: Introduction
1.1 Introduction to HIV
1.1.1 HIV biology
Human immunodeficiency virus type 1 (HIV-1) is an agent that causes acquired
immunodeficiency syndrome (AIDS) in humans. It belongs to the Retroviridae family and the Lentivirus
genus (Capriotti T, 2018). HIV was first discovered in 1981 when an unusually high number of
opportunistic diseases and rare malignancies were reported in the homosexual men population (CDC,
1981, Greene WC, 2007). In this context, the French scientists Françoise Barré-Sinoussi and Luc
Montagnier discovered this pathogen (Rogowska-Szadkowska D, 2008, Pincock S, 2008), being awarded
the Nobel prize in 2008 in Medicine or Physiology for their discovery (Kurapati KR, 2015).
Lentiviruses can remain dormant for a long time causing a latent infection. This is accomplished
through the reverse transcription of viral RNA to DNA and its latter integration into the host genome.
These two main viral strategies are accomplished by the reverse transcriptase and the integrase proteins,
both encoded by the pol gene. This integration can occur at any location of the genome, but there are
certain areas more commonly used (Ciuffi A, 2008). Once the lentivirus is integrated, it may divide using
its machinery or remain dormant, dividing along with the host cell genome and thus, creating viral
reservoirs that result in life-long infections (Craigie R, 2012).
1.1.2 Origins of a pandemic
HIV origins have been deeply studied by scientists since it became a pandemic. This virus is
related to a group of simian viruses that also can cause immunodeficiency in primates and macaques, and
are collectively known as simian immunodeficiency virus (SIV) (Sharp PM, 2011). SIV gave origin to
both HIV-1 and HIV-2, and to different SIV strains that infect numerous kinds of simian. Interestingly
SIV has been detected across 40 primate species (Klatt NR, 2012). Although the most common
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transmission of a SIV strain occurs within the same species, it has also been reported that it has crossed to
different species, finding either a “dead-end” or a new host in which a new strain develops (van Rensburg
EJ, 1998, Van Heuverswyn F, 2006). And thus, this virus been able to recombine with other SIV strains
creating new strains of HIV (Souquière S, 2001, Aghokeng AF, 2007).
The closest genetically related SIV to HIV-1 is the one found in chimpanzees (SIVczp) (Sharp
PM, 2005). Therefore, many studies have been focused on this strain. Through the sequencing of different
strains of SIVcpz, was found that it is highly related to two SIV strains that probably were recombined to
form this virus. Both LTRs and the gag, pol, vif, vpr, and nef genes are closely related to the SIV strain
originally from red-capped mangabeys. While the env, rev, tat and vpu genes are more similar to the SIV
originally from Cercopithecus species (Bailes E, 2003). This viral recombination event in chimpanzees is
likely to have happened due to the predation of smaller simians (Goodall J, 1986).
It was recently reported that gorillas could represent also a reservoir of SIV for human infections
(SIVgor) (Van Heuverswyn F, 2006). Although it is not well understood how gorillas got infected with
SIV, it is clear by genetic analysis of SIVgor that is closely related to SIVcpz. The way that SIV was
transmitted to humans remains unclear, nonetheless, it is suspected that this might have happened in a
similar way that occurred previously between different primate species. This would include fighting and
by human hunting of apes, thus causing a subcutaneous or mucosal exposure to ape blood or infected
body fluids (Peeters M, 2002).
The world pandemic HIV-1 includes 4 different lineages, known as M, O, N and P, ordered here
from most prevalent to least and arising from independent cross-species transmission events (Sharp PM,
2011). Even though all these groups are capable of originating AIDS, the world pandemic is being caused
only by members of the M group, being groups O, N, and P only reported in patients from African
countries (De Leys R, 1990, Gürtler LG, 1994, Mauclère P, 1997, Peeters M, 1997, Simon F, 1998,
Vallari A, 2010, Plantier JC, 2009, Vallari A, 2011). It has been also established that the M and the N
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group are originally from chimpanzees (Keele BF, 2006, Van Heuverswyn F, 2007) while the P group is
suspected to have crossed the barrier species from gorillas. The O group origin remains a mystery (Sharp
PM, 2011).
The emergence of the M group has been dated to around 1920 and the initial location is thought
to be Kinshasa, the capital of the Democratic Republic of the Congo (Korber B, 2000). During these
years, the urban expansion of the population probably made necessary an increase of commerce
(Worobey M, 2013), which was made through the same rivers that connected the chimpanzee reservoir
containing the predecessor of the HIV-1 M group in the southeast of Cameroon (Sharp PM, 2008). This
pandemic is estimated to have caused a total of 60 million infections and over 25 million related deaths
around the world (Merson MH, 2008).
Within the M group, there are 9 different subtypes (from A to K) and a wide variety of hybrids of
these subtypes known as circulating recombinant forms (CRFs) (figure 1). Although most of the research
is based on subtype B, this strain only represents 12% of the global pandemic. The distribution of these
particular strains is mainly the Americas, Western Europe, and Australia (Hemelaar J, 2012, HIV
databases, 2019).
1.1.3 AIDS
HIV disease has 3 different stages. Acute HIV infection in which patients manifest the following
symptoms for a couple of weeks: headache, fever, pharyngitis, lymphadenopathy, and myalgia (Capriotti
T, 2018, Burgess MJ, 2013). The following phase is chronic HIV infection which, if not treated causes
the last stage, AIDS. In this final stage, patients are more susceptible to be affected by opportunistic
diseases (May MT, 2014). AIDS is a consequence of the tropism of HIV, which targets CD4+ T cells
(also called Helper T cells). These cells are essential to fight pathogens, but HIV causes a decrease in
their concentration in the blood to less than 200 CD4+ T cells per cubic millimeter of blood, compared
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with about 1,000 CD4+ T cells for healthy people (Naif HM, 2013, U.S. Department of Health and
Human Services, 2017) Macrophages are also targeted by HIV, creating reservoirs of the virus in the
organism that cause a lifelong infection in the patients (Ciborowski P, 2006).
1.1.4 HIV transmission
HIV is usually considered a sexually transmitted disease because it is the most common
transmission route. However, needle sharing or other equipment to prepare drugs for injection with
someone who has HIV is extremely risky behavior. Depending on the temperature and other factors, it has
been reported that this virus could survive in a used needle for up to 42 days. Similarly, receiving a blood
transfusion, organ, or tissue that is infected would result in HIV transmission. Finally, Mother-to-child
transmission is possible during pregnancy, birth, and breastfeeding, however when a mother is taking
anti-HIV medicine (called antiretroviral therapy (ART) to fight the infection and reduce her viral load)
the transmission chances are significantly reduced (CDC, 2018b).
1.1.5 Most common opportunistic infections
The more common opportunistic infections that AIDS patients suffer in the US are Candidiasis
(of bronchi, trachea, esophagus, or lungs), pneumonia (caused by Coccidioidomycosis, Cryptococcosis,
Isosporiasis, and Pneumocystis carinii pneumonia), long-lasting diarrhea (caused by Cryptosporidiosis or
by a Salmonella septicemia), Cytomegalovirus diseases, Encephalopathy, Herpes simplex diseases,
Histoplasmosis, Tuberculosis, Mycobacterium related diseases, Progressive multifocal
leukoencephalopathy, Toxoplasmosis of brain and Wasting syndrome due to the loss of muscle mass
(CDC, 2018a). Additionally, there are different kinds of cancer-related to AIDS: Kaposi sarcoma, nonHodgkin lymphoma, invasive cervical cancer, anal cancer, Hodgkin lymphoma, hepatocellular carcinoma,
skin cancer, head, neck, and lung cancer (Wang CJ, 2014, National Cancer Institute, 2017). Moreover,
HIV-1 can cause dementia by the infection of differentiating macrophages that cross the blood-brain
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barrier and keep an activated status inside the brain, thus releasing high levels of neurotoxins and
ultimately leading to mental and/or even motor impartment (Nottet HS, 1995).

HIV-1

M

N

O

P Groups

A B C D E F G H I J K CRFs Subgroups
Figure 1: HIV-1 groups and subgroups

1.1.6 Current HIV global impact
HIV disease is still a serious health issue for some parts of the world. According to the Centers
for Disease Control and Prevention, in 2017 about 36.9 million people were living with HIV around the
world, of whom 21.7 million were receiving ART to treat HIV. ART has helped to decrease the number
of AIDS-related deaths, but access to this treatment is not universal. An estimated 940,000 people died
from AIDS-related illnesses and there were about 1.8 million new infections of HIV worldwide. SubSaharan Africa, which bears the heaviest burden of HIV and AIDS worldwide, accounts for about 66% of
all these new HIV infections. Other regions significantly affected by HIV and AIDS include Asia, the
Pacific, Latin America, the Caribbean, Eastern Europe, and Central Asia (CDC, 2017, WHO, 2017).
Additionally, according to the World Health Organization (WHO), the percentage of pregnant women
living with HIV who received ART to prevent mother to child transmission varies from more than 80% to
a concerning less than 25% in some countries. Causing about 180,000 new infections and 110,000 HIVrelated deaths in 2017 (Figure 2). (WHO, 2017)
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Figure 2: Global HIV epidemic data according to WHO
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1.2 HIV biology
1.2.1 HIV genome and proteins
HIV is a complex virus that uses several proteins to accomplish its life cycle. These proteins
could be divided into i)The structural proteins: Polymerase (Pol), Envelope (Env), and Group-specific

Figure 3: Map from HCV sequence database
(https://hcv.lanl.gov/content/sequence/HIV/MAP/landmark.html)

antigen (Gag). ii) Regulatory proteins: Trans-activator of transcription (Tat) and Regulator of the virion
(Rev). And accessory regulatory proteins Virion infectivity factor (Vif), Viral protein Unique (Vpu),
3: factor (Nef), and Viral protein R (Vpr). The synthesis of each protein is
NegativeFigure
regulatory

accomplished in one of the three reading frames. The role of each protein will be explained below in the
context of its function in the viral life cycle.
1.2.2 HIV cycle inside the cell
The first step is the binding between a viral particle and a target cell. This is accomplished by the
interaction between the viral Env glycoprotein gp120 with a CD4 receptor. Together with this binding,
the viral particle’s tropism will determine the binding to either CXCR4 or CCR5 cellular coreceptors
(Maartens et al., 2014). Once the viral particle has been anchored to the cell membrane, the
transmembrane Env glycoprotein gp41 enhances the fusion of the viral membrane and the cellular
7

membrane, releasing the HIV capsid into the cytoplasm. Each viral particle contains several essential
elements for HIV replication, such as Gag, Gag-Pro-Pol polyprotein, Env, two copies of viral genomic
RNA, the tRNA primer, and a lipid envelope. But viral particles also incorporate other elements whose
presence is not completely clear, such as cellular and viral accessory proteins (Sundquist and Krausslich,
2012).
The de-capsidation of the virus releases all the viral components in the cytoplasm, thus allowing
the different mechanisms to start at the same time. Most of the viral accessory proteins are able at this
point to carry out different functions in the host cell. Such as Nef and Vpu which carry out two different
mechanisms to downregulate CD4 and thus avoiding the possibility of superinfection. Nef interacts with
the vesicular trafficking machinery affecting regular cell signaling and down-regulating CD4 by
enhancing its uptake from the plasma membrane into the endosome–lysosome compartment.
(Basmaciogullari and Pizzato, 2014) On the other hand, Vpu mediates the degradation of CD4 in the
endoplasmic reticulum by linking it to SCF ubiquitin ligase and leading it to the endoplasmic-reticulumassociated degradation pathway (Lindwasser et al., 2007).
Meanwhile, the reverse transcription of the viral ssRNA to dsDNA takes place. During this
process, a viral high molecular weight complex is formed, which is also known as the pre-integration
complex (PIC). It is composed of the following viral proteins: matrix, nuclear core, integrase, reverse
transcriptase (RT), and Vpr proteins. PIC crosses the nuclear membrane and integrase the viral dsDNA
into the host genome of dividing cells. Both LTRs founds in the viral genome together with the PIC
complex play the main role during viral integration. In the cells that are not dividing HIV’s life cycle
stops here creating a reservoir (Johnson, 2011, Pilakka-Kanthikeel et al., 2011, Kurapati et al., 2015).
Once the virus is integrated, the LTRs enhance the transcription of viral RNA. This is
accomplished by the interaction between the Tat protein and the TAR region found between the
nucleotides +1 and +60 of the LTR. Together with Tat, there are cellular factors that interact with the
8

LTR, all of them playing an important role in trans-activation. Following the production of viral mRNA,
Rev mediates its export to the cytoplasm (Rosen, 1991) where it will be translated into one large
polyprotein. This large polyprotein is then processed in cytosolic polysomes into Gag, Gag-Pro-Pol, and
most accessory viral proteins. On the other hand, viral protein Env, Vpu, and the viral membrane proteins
are assembled in the rough ER (Sundquist and Krausslich, 2012).
Finally, all viral proteins gather together to form the virion particle. This is achieved by the
interaction of Gag with other proteins and with RNA, which results in the formation of an immature unexcise viral particle (Freed, 2001). At this point, the viral protein Vif carries out probably its most
important function in the viral cycle. Vif interacts with the cellular protein APOBEC3G and excludes it
from virions. This prevents APOBEC3G from deaminating cytidine, which leads to the misread by the
RT as thymidine and to the insertion of alanine instead of guanine during the synthesis of cDNA second
strand (Strebel, 2013).
The final excision from the host cell is thought to be accomplished through the interaction
between Gag and cellular proteins, such as KIF4 and components related to the traffic of vesicles within
the cell (Martinez et al., 2008), but the exact mechanism remains unclear. In this step, Vpu prevents the
cellular blockage of viral release by interacting with BST-2 (Strebel, 2013).
Maturation of the viral particle is achieved when the HIV-1 protease cleaves the Gag protein
forming Matrix, Capsid, Nucleocapsid, and p6. The maturation of the viral particle has extraordinary
importance. Unmatured Gag protein directs the gathering and assembling of the viral components in the
plasma membrane, while mature Gag products direct the viral components to the nucleus in the newly
infected host (Freed, 1998).
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HIV is also able to infect different cells by cell to cell transmission; the way HIV follows one
infection route or another is not completely understood but it is thought that is dependent on the initially
infected cell type.
1.2.3 RNA splicing
HIV replication efficient replication requires a very specific RNA splicing in the infected cells.
This virus uses its cis-elements, together with host proteins to produce over 40 different spliced mRNA
from its full-length RNA transcribed by RNA polymerase II in the nucleus (Stoltzfus, 2009). HIV uses
both, spliced mRNA and full-length RNA to produce viral proteins. Additionally, full-length RNA
produced becomes the genome of future virions. Transport of spliced and un-spliced mRNA is
accomplished by the mediation of Rev, which acts as an adaptor between viral RNA and the Crm1dependent nuclear export pathway (Cullen, 2003).
During the first stages of infection, HIV enhances the transport and translation of completely
spliced regulatory proteins mRNAs to the cytoplasm, such as Tat, Rev, and Nef. At a later time point of
infection, enough Rev protein is produced allowing the transport of unspliced viral mRNA of 9 kb and
incompletely spliced mRNAs of 4 kb which include Env, Vif, Vpr, and Vpu proteins (Klotman et al.,
1991, Michael et al., 1991). However, Vif Tat and Vpr mRNAs are present in low abundance compared to
Env, Nef, and Rev mRNAs, representing Vpr only 2% of the total incompletely spliced mRNA (Purcell
and Martin, 1993). Interestingly, Vpr has shown to inhibit Cellular splicing in HIV-infected cells by
interacting with the spliceosomal protein SAP145 (Kuramitsu et al., 2005, Hashizume et al., 2007).
1.2.4 HIV target cells and cell-to-cell transmission
The main target cell for HIV is CD4 + T cells. However, it has been reported that HIV is also
able to infect other cell types such as macrophages. Macrophages can get infected by the interaction of
the virus with CD4 and co-receptor or by the CD4 independent endocytosis of the virus, both leading to
10

infection(Arainga et al., 2017, Gobeil et al., 2012). On the other hand, dendritic cells (DC) are hardly ever
infected by HIV. However, they can interact with the HIV envelope and remain bound until they interact
with CD4 positive cells, enhancing cell to cell transmission (Gummuluru et al., 2014). This wide variety
of routes that HIV can take allows the depletion of CD4+ T cells and the creation of reservoirs, leading to
a lifelong infection and AIDS.
1.2.5 Unanswered questions
There are lots of publications regarding different aspects of the viral life cycle, infection, viral
evasion of the immune system, and pathogenesis. However, there are still many critical questions that
remain unanswered. There is a stage of HIV infected patients in which they are called “Long-term nonprogressors” (LTNP). These patient types never develop AIDS, even though they still will have a lifelong HIV infection. Because it is not fully understood how HIV causes AIDS or LTNP, it is complicated
to prevent the disease. Considering all the publications regarding different Vpr mutants, and their
possible effect on progression to AIDS, we aim to decipher how Vpr different mutants affect the
progression to either AIDS or LTNP.
1.3 Vpr overview
1.3.1 Vpr characteristics
Vpr is found in many types of lentivirus including Human Immunodeficiency Virus type 1 (HIV1), type 2, and Simian Immunodeficiency Virus (SIV). It has a critical role in pathogenesis and replication
and is classified as a viral regulatory protein (Cohen E. A., 1990, Majumder B., 2009). The vpr gene is
highly conserved across many types of lentiviruses, suggesting the biological importance of Vpr in the
life cycle of lentiviruses (Stivahtis G.L., 1997, Tristem M., 1992). Vpr is 96 residue long protein encoded
by the vpr gene, which overlaps with vif and tat (Figure 3). However, each of these proteins is synthesized
in a different reading frame (Emerman, 1996).
11

Vpr structure is simple, with three

-helices located in between positions 17-33, 38-50, and 55-

77 surrounded by flexible domains. The N- and C-terminal domains are negatively and positively
charged, respectively (Morellet et al., 2003, Planelles and Barker, 2010). Vpr interacts with several
cellular and viral proteins, including other Vpr proteins, and forming oligomers. (Hadi K, 2014, Planelles
and Benichou, 2009). Additionally, Vpr possesses residues across the three

-helices and C-terminus that

act as nuclear localization signals allowing it to enter the nucleus and enhance viral replication (Sherman
MP, 2001). Arginine residues found between amino acid positions 73 and 96 are thought to help Vpr to
cross lipid bilayers and aid in its transducing properties (Planelles and Barker, 2010).
The mechanism of nuclear import differs between types of host cells. In macrophages, Vpr enters
the nucleus as part of the PIC complex thereby enhancing transport (Nitahara-Kasahara Y, 2007), while in
lymphocytes it behaves as a trans-activator (Iijima S, 2004).
1.3.2 Functions and effects in disease progression
It is likely that this accessory protein plays a crucial role in counteracting cellular antiviral factors
and that this activity would be highly related to its morphology and interactions with other Vpr proteins or
host factors (Yan N., 2012). Although Vpr is a late gene, the mature virion carries multiple copies of the
protein inside the capsid, and thus it is active during the early stages of infection (Hrimech M, 1999, Poon
B, 2003). Vpr carries out different functions during the viral infectious cycle. It is part of the PIC, which
facilitates the translocation of viral RNA to the nucleus of non-dividing cells (Zhao LJ, 2004).
1.3.3 Cell cycle arrest
The presence of Vpr has been shown to enhance the production of virus in T cells (Hadi K, 2014).
This effect could stem from several of the interactions that Vpr has with the host cell, such as cell cycle
arrest and apoptosis. Vpr mediated G2 phase cell cycle arrest has been widely documented both in in vitro
and in CD4 + lymphocytes from HIV-1 infected individuals (Rogel ME, 1995, J He, 1995, J B Jowett,
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1995, Re F, 1995, Zimmerman et al., 2006). It is not completely understood the mechanism by which G2
arrest is accomplished. However, the study of Vpr interactions with the ubiquitin ligase complex has
resulted in very interesting findings. It has been shown that Vpr interacts with an unknown protein
through a leucine-rich motif located between residues 60 and 68 (Zhao et al., 1994). This protein interacts
with Damage DNA-specific binding protein 1 which is an adaptor for Cullin 4. This complex recruits an
ubiquitin ligase complex that has a role in genome stability, DNA replication, and cell cycle checkpoint
control (Angers et al., 2006, Higa et al., 2006, Jin et al., 2006, Planelles and Barker, 2010). It is proposed
that Vpr binds an unknown protein that gets ubiquitinate by this complex and degraded, thus activating
the G2 checkpoint (Dehart and Planelles, 2008). Additionally, the truncation of the last 18 residues in the
C-terminal domain prevented G2 arrest, suggesting that this section also binds a protein whose
ubiquitination and degradation, leads to G2 arrest (Planelles and Barker, 2010). During this phase of cell
growth, the viral promoter, called Long Terminal Repeat (LTR), is more active (Goh WC, 1998).
Interestingly, Vpr dependent activation of ATR leading to the downstream phosphorylation of BRCA1
and upregulation of GADD45

has been associated with apoptosis and G2 cell cycle arrest (Andersen et

al., 2006). ATR is a sensor for replication stress that can trigger the G2 checkpoint and studies have
shown that depletion of this protein diminished Vpr induced G2 cell cycle arrest (Roshal et al., 2003).
Moreover, it has been observed in other studies that proteins downstream of the ATR pathway that have a
direct effect on cyclin B-p34 activation, get hyperphosphorylated. These are CDC25C or wee1 which get
deactivated and activated respectively (Re et al., 1995, Emerman, 1996). Moreover, Carlos M. C. de
Noronha's research group reported Vpr induced disruption of the nuclear envelope, which theoretically
could lead to the activation of the ATR pathway (de Noronha et al., 2001). These studies collectively
support the effect that Vpr has on the ATR pathway and a possible explanation for cell cycle arrest and
cell death.
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1.3.4 Vpr induced cell death
Numerous studies show that Vpr triggers cell death in T lymphocytes. Once again, multiple
divergent pieces of evidence make elusive the exact mechanism. Vpr causes mitochondrial membrane
permeabilization by binding the Adenine Nucleotide Transporter (ANT) found in the permeability
transition pore, resulting in the release of apoptotic factors from the mitochondrial membrane (Jacotot E,
2000, ME, 2017). However, it has been observed that cell death caused by this permeabilization trigger
necrotic pathways rather than apoptotic (Nakagawa et al., 2005).
Another field of study has been the relation between G2 cell cycle arrest and cell death. It has
been proposed that apoptosis is a final effect of the checkpoint blockade that inhibits cell cycle
progression. This study showed that Vpr-induced apoptosis requires Bax and not ANT. Additionally, cells
synchronized in the G1/S phase eliminated Vpr pro-apoptotic effects (Andersen et al., 2006).
Contradictory, other studies observed that infected cells are more commonly apoptotic during G1 or S
phase, while cell cycle arrest occurs in M/G2 phase. Therefore, is not clear whether apoptosis is a
consequence or not of the cycle arrest observed in the M/G2 phase and if it is an apoptotic independent
process (Bolton DL, 2007, Stromájer-Rácz T, 2010, ME, 2017). Finally, circulating Vpr has been
suggested to cause apoptosis as well, in this case by the permeabilization of cellular membrane to calcium
and magnesium (Levy DN, 1995, Aukrust P, 1994, Macreadie IG, 1996).
Due to the effects of Vpr on HIV-1 infected cells, different mechanisms have been proposed to
explain how this regulatory protein enhances disease progression. A) Promoting early T cell activation, by
enhancing NFAT to prime non-activated T cells for productive infection (Höhne K, 2016). B) Inhibiting
T cell proliferation and enhancing cell death (Stivahtis G.L., 1997). C) Inducing the infection and
activation of virus production from latency in macrophages, creating drug-resistant HIV reservoirs (Levy
DN, 1994, Cohen EA, 1990, Balotta C, 1993).
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There is controversy regarding what is the main death pathway followed by HIV infected T cell
lines. Some groups support that most cell death is due to apoptosis rather than necrosis (Pan et al., 2014).
While other groups verily detect any apoptosis signs and suggest that cells are dying through necrosis
(Bolton et al., 2002). Our results definitive support for the last group results. Interestingly, another cell
death pathway is proposed as a consequence of HIV infection. In this case, pyroptosis has been observed
in bystander T cells while apoptosis was observed in infected T cells in the same population. In this case,
pyroptosis was suggested to be triggered by aborted HIV infection (Doitsh et al., 2014).
1.3.5 Oligomerization
A key aspect of Vpr pathogenesis is its ability to oligomerize, allowing it to perform different
functions determined by the number of subunits in the complex (Zhao LJ, 1994). This interaction allows
through a zipper-like motif formed by the hydrophobic region formed from side chains on one side of the
third helix (Schuler et al., 1999). It has been observed that only oligomerizable Vpr is packaged into
virions, non-oligomerizable Vpr however, is still able to inhibit cell proliferation and enhances cell death
(Bolton DL, 2007, Venkatachari NJ, 2010).
1.3.6 Additional Vpr interactions with cellular proteins and mechanisms
In addition to the interactions above, Vpr interacts with a wide range of proteins and cellular
mechanisms, making it harder to understand the global effect that this protein has in a single cell. The
following Vpr interactions have been reported: i) Interactions with the DNA repair machinery
(specifically with the nuclear form of uracil DNA glycosylase, with the human homolog of S. cerevisiae
Rad23 and Vpr induces a genotoxic stress signal) ii) Interactions with cell cycle regulatory elements, (143-3 protein family, ATR, Cdc25, wee1,p21WAF, Sp1, p300 and the Ubiquitin/Proteasome system). iii)
With pro-apoptosis and anti-apoptosis machinery (Heat shock protein 70). iv) With the nuclear pore and
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nuclear transport elements. v) With splicing regulators (SAP145). And finally, vi) with cyclophilin A and
with the glucocorticoid receptor (Paul Spearman, 2009).
1.3.7 Vpr mutants
The fluctuation of CD4 T cell levels is commonly observed in HIV patients. Patients that
maintain normal levels of CD4 T cells are classified as long term non-progressors (LTNP) while those
that experience a rapid decrease in CD4 T cells are classified as rapid progressors (RP); rapid progressors
usually develop AIDS 5 to 8 years after infection (Shioda T, 2006). Mutations in the regulatory protein
Vpr have been proposed as the causative agent of the phenotypic differences observed in infected patients
(Lum JJ, 2003, Rodés B, 2004).
There is a long list of mutations that have shown to enhance cell death, such as non-conservative
mutations in L64 (Jian and Zhao, 2003), or that are suspected to enhance AIDS progression such as
R36W, L68M, and R85Y (Hadi K, 2014, Jacquot et al., 2009). On the other hand, multiple mutations
have been shown to produce LTNP phenotypes, such as Q3R, Q65R, F72L, and R77Q (Hadi K, 2014,
ME, 2017). Combination of single point mutations has also been reported to affect the cytopathicity of
HIV in different tissues, such as A55 and T63, which have been associated with LTNP as well(Kamori et
al., 2017).
However, there is some controversy regarding the effect of these mutations since opposite
phenotypes have been reported about them, making it hard to understand the way that Vpr mutations
affect pathogenesis. (Jian and Zhao, 2003, Hadi K, 2014).
1.3.8 R77Q
The R77Q Vpr mutant has been suggested to produce an LTNP phenotype in HIV infected
patients. While this mutation has been found in several LTNP patients and has also been reported to
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produce low virus replication (Lum JJ, 2003, Mologni D, 2006, Hadi K, 2014), other studies have shown
no correlation between them (Cavert W, 2004, Chui C, 2006), contradicting this hypothesis. The 77th
position of this protein is located in the helical domain III. According to previous reports, a mutation in
this position from arginine to glutamine is found in 46.4% of LTNPs and 29.3 of RPs (Hadi K, 2014).
1.3.9 R36W
On the other hand, the Vpr R36W mutant has been categorized as an RP mutation, showing
comparable replication rates to wild-type strains (WT). R36W also has an enhanced capacity to
oligomerize which could result in more effective pathogenesis. It has also been reported to be deficient in
causing cell cycle arrest, potentially resulting from its enhanced oligomerization. The 36th position in this
protein is located in the loop that links domains I and II. A mutation in this position from arginine to
tryptophan has been observed in 17.7% of RP patients but has not been found in LTNP (Hadi K, 2014).
1.4 Anti-HIV strategies
Several pharmaceutical companies and research groups have developed a wide variety of antiviral drugs that target HIV. Although these treatments have proved to highly expand the life expectancy
of patients, there are some disadvantages. Such as i) These drugs are not curative, so patients have to use
them for the rest of their lives to avoid viral rebound. ii) The drugs are expensive; thus, third world
countries cannot have access to them. iii) These treatments usually have tough side effects, causing a
quick rebound in patients that have to stop using them. Due to these inconveniences, nowadays research is
focused on finding an entirely different approach, based on genome therapies, that could prevent AIDS
indefinitely.
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1.4.1 ART and limitations
So far, the most effective strategy to target this virus has been during its replication as its high
mutation rate makes it difficult to develop vaccines that help the immune system to recognize envelope
antigens (Kim JH, 2015). Over the last decades a wide number of antiretroviral drugs, which target
specific stages of the viral replication cycle, have been developed; such as interference with HIV
coreceptor binding, blocking cell membrane fusion, inhibition of reverse-transcription from RNA to
DNA, disruption of the integrase that inserts the viral DNA into the host genome, and blocking the
protease that helps to generate new virus peptides by cleaving precursor proteins (Arts EJ, 2012).
However, the high mutation rate of HIV provides a way for this virus to escape from the effect of
antiretroviral drugs and the immune system as well. HIV-1 resistance development has been widely
studied over the past decades. There are several processes by which HIV-1 develops resistance to
antiretroviral therapy (ART) and recognition by the immune system, including (i) Mutations in genes
encoding polymerase (Shailesh K. Choudhary et al., 2009) that make HIV-1 resistant to ART. (ii)
Changes in the viral Env causing amino acid substitutions in antigenic proteins. Mutations produce loose
of N-linked glycosylation sites and substitutions in CD4 binding sites and in CD4-induced epitopes,
which helps the virus evolve under antibody selection (Ince et al., 2010). (iii) Resistance to anti-HIV-1
drugs can also result from sub-lethal A3-mediated G-to-A mutation (Sato et al., 2010); this results from
the action of APOBEC3 proteins, specially APOBEC3D, APOBEC3F, and APOBEC3G which induce Gto-A hypermutations in the HIV-1 genome. When these proteins are modified APOBEC3D and
APOBEC3F preferred sites of actions are related to anti-HIV-1 drug resistance (Sato et al., 2014). It was
also detected that HIV-1 escapes from anti-sense RNA encoded by VRX494 by cellular double-stranded
RNA adenosine deaminase, which produces modifications in the viral sequence. Nevertheless, these
modifications usually result in defective replication (Mukherjee et al., 2010). Besides, HIV creates ARTresistant reservoirs, forcing patients to take ART for the rest of their lives to avoid viral replication. Most
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antiretroviral drugs, besides being highly expensive, have failed to destroy the HIV reservoirs and have
allowed lifelong infection in HIV infected patients (Matreyek KA, 2012).
1.4.2 Vaccine development
In the last 40 years, there has been a lot of research focused on developing an effective anti-HIV
vaccine that could prevent or stop the disease with a wide variety of strategies (Seddiki et al., 2020, Leal
et al., 2020, Fries et al., 2020). Many of them are safe and to induce an immune response. However, they
have failed to protect against HIV infection, and consequently, there is not yet any effective vaccine
(Laher et al., 2020).
1.4.3 Genome therapies
Many gene therapies have been proposed to stop HIV infection. These therapies involve the use
of different tools, such as Zinc Finger Nucleases, Transcription activator-like effector nucleases, and
Clustered Regularly Interspaced Short Palindromic Repeats.
Hematopoietic stem cells would usually be transduced with lentiviral vectors or modified with
one of the previous tools to include/exclude a sequence of interest that will be presented in all the
daughter cells.
In the last decade, there have been many publications with different strategies developed. The
target of these therapies has been very wide, from targeting the entry receptors CD4, CCR5, and CXCR4
(Allen et al., 2018), to studying the direct effect of targeting the HIV genome both in vitro (Wang G.,
2016) and in vivo using engrafted humanized mice (Bella et al., 2018).
Additionally, RNA Interference or Micro RNAs have been also tested to silence HIV expression.
These small RNA fragments inhibit the translation of the target mRNA, which may be used to directly
target the HIV 3’ UTR or to target the mRNA proteins that play a crucial role in HIV replication, thus
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inhibiting its production. In both cases, the HIV life cycle should be stopped (Fowler and Saksena, 2013,
Harwig et al., 2014, Swaminathan et al., 2014, Swaminathan et al., 2013). Many of these studies have
shown promising results and could be key for the development of an HIV therapy that could be used
worldwide.
1.4.4 AIM of the HIV study
This study is focused on clarifying what should be the expected phenotype and behavior of a T
cell line after HIV Vpr mutant infection. We analyze the replication rate, G2 arrest, and apoptotic
phenotypes of HUT78 cells infected with either HIV-1 expressing either wild-type Vpr, R36W, R77Q, or
Vpr null mutants to better understand the role that Vpr plays in viral replication and T cell killing
pathways as they relate to disease progression. This study is currently under review in the journal
Retrovirology.
1.5 SARS-CoV-2 pandemic
1.5.1 Human Coronavirus
Coronaviruses (CoV) are enveloped RNA viruses that cause respiratory tract infections. Its
genome is coded in a positive, single-stranded RNA, varying in size from 26 to 32 kilobases (Wang et al.,
2020a). It is named after the crown-shape observed in the surface of virions formed by protein spikes.
They belong to the Nidovirales order and coronaviridae family (Yang et al., 2020) There are four genera
of known CoV, which belong to the subfamily Orthocoronavirinae, and they can cause disease in humans.
These are -coronavirus, -coronavirus, -coronavirus, and -coronavirus. 4 specific species cause
common cold symptoms in humans affecting the respiratory tract, these are 229E, NL63, OC43, and
HKU1 (Hossain et al., 2020). Additionally, another two had caused deadly outbreaks in the past 20 years
before this outbreak (Faridi, 2018, Mackie, 2003). These 2 viruses are interestingly genetically related to
Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) and they are Severe Acute
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Respiratory Syndrome coronavirus (SARS) and Middle East Respiratory Syndrome coronavirus (MERS)
(Chan et al., 2020a, Chen et al., 2020).
1.5.2 SARS-CoV-2 pandemic impact
A novel coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
was identified in China in December of 2019, causing an ongoing pandemic. The earliest reports of this
disease, known as COVID-19 (Coronavirus Infectious Disease 2019), took place from December 18th to
December 29th of 2019 (Hossain et al., 2020). During this period, 5 patients were hospitalized in the
central Chinese city of Wuhan and one of them died (Ren et al., 2020). To date, SARS-CoV-2 has spread
to 213 countries (https://coronavirus.jhu.edu/). Over 38 million infections and more than 1,000,000 deaths
have been reported so far, impacting public health systems, forcing quarantine procedures, and
significantly affecting the economy around the globe (CDC, 2019, Acter et al., 2020, Abrams and Szefler,
2020). In the second quarter of the year 2020 in the US the COVID-19 crisis has caused an increase in
unemployment levels in June to a rate of 11.1 % and a 5% reduction of the gross domestic product
(Statista, 2020). Currently, intensive efforts are taking place at an unprecedented speed to discover
therapeutics, re-purpose drugs, and develop vaccines to cure and prevent SARS-CoV-2 infection (Zhang
et al., 2020, Elmezayen et al., 2020).
1.5.3 Origins of the pandemic
The pandemic origin remains elusive, mainly because of the economic consequences that this
finding could have for responsible countries or for countries that would not have taken the necessary
precautions to prevent it. However, something that is suspected is that SARS-CoV-2 may have crossed to
humans from an unknown reservoir animal species as SARS and MERS did in the past outbreaks (Cui et
al., 2019). Interestingly, a group has recently shown that SARS-CoV-2 is closely related to a -CoV
found in bats which belongs to the sarbecovirus subgenus and the coronaviridae family (Zhu et al., 2020).
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Conversely, another group has reported a high similarity between a bird coronavirus with SARS-CoV-2
(Lu et al., 2020). A third group showed that this virus genome is closely related to the SARS genome
(with up to 80% homogeneity) and also related to MERS (up to 40%)(Lu et al., 2020).
1.5.4 Transmission
Although limited knowledge is currently available about the transmission of COVID-19, it has
been observed that the droplets produced by coughing or sneezing of infected individuals are capable of
enhancing human-to-human transmission especially at short distances (Li et al., 2020). Additionally, it
has been observed that this virus is genuinely resilient. Some groups have reported that the virus may
survive for up to a few days on surfaces (Ali and Alharbi, 2020), and our preliminary tests showed that
this virus is completely resistant to dry cycles, not losing the capability of infected or decreasing the
concentration of effective viral particles after been completely dried in a carrier for 2 hours (data not
shown), showing the need for effective and available disinfectants. Thus, the transmission of this disease
has been reported after exposition to contaminated fomites, including medical equipment that was used to
treat infected patients (Ong et al., 2020). For these reasons, proper hygiene techniques are been widely
and highly recommended to the population, such as using hand sanitizer, enforcing the use of masks,
prohibiting large gatherings, avoiding contact with infected patients, etc.
One of the biggest difficulties to stop the spread of the disease has been the appearance of
asymptomatic individuals that unknown are carriers of the disease. These individuals can enhance humanto-human transmission due to the lack of precautions that they take (Chan et al., 2020b). With all this
evidence of the virus resilience, more studies are approaching the possibility that SARS-CoV-2 may be
transmitted directly as an airborne pathogen. Although more studies need to be performed, it has been
reported a lower risk of infection in ventilated or outdoors locations (The Lancet Respiratory, 2020).
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1.5.5 Symptoms and pathogenesis
The most common reported symptoms of COVID-19 have been dry cough, sore throat,
congestion or runny nose, fever or chills, shortness of breath or difficulty breathing, fatigue, muscle and
body aches, headache, new loss of taste or smell, dyspnea, nausea or vomiting and diarrhea (Subbarao and
Mahanty, 2020, CDC, 2020c). These symptoms are common to other lower respiratory tract and lung
infections. However, this disease may affect many other organs and tissues such as the heart, blood
vessels, nervous system, liver, and kidneys. In the most severely ill patients, an excessive response of the
immune system has caused a whitening of the lungs, probably due to a storm cytokine that ultimately may
cause the patient to die (Sungnak et al., 2020).
1.6 Anti-SARS-CoV-2 strategies
1.6.1 Therapies against COVID-19
No efficient therapy to cure COVID-19 is available to date, neither a vaccine that confers
immunity against SARS-CoV-2 infection approved by the FDA (CDC, 2020b, Le et al., 2020). Some
drugs such as Remdesivir have shown the ability to reduce in about 3 days the number of days that
patients need to recover while other drugs like Dexamethasone have helped to reduce the overall
mortality rate of patients under invasive mechanical ventilation by about 12% (Wang et al., 2020b, Group
et al., 2020). Although hopeful, these drug-based treatments are still limited in their specificity and
efficacy to cure and contain the spread of COVID-19 (Triggle et al., 2020). Vaccination is the greatest
hope for lasting protection against SARS-CoV-2 infection. To date 44 vaccine candidates are in clinical
trials and 154 more are in preclinical stages (WHO, 2020). Even though some vaccine candidates are
moving fast through the various clinical testing phases, a full evaluation of a vaccine’s efficacy and the
duration are still to come, hopefully within the next few years (Su et al., 2020). Previous data have shown
that the protective effects of antibodies generated against COVID-19 may have a limited duration from 40
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days to up to 5 months (Zhao et al., 2020, Kirkcaldy et al., 2020). Thus, even though a vaccine will
shortly become available, its protection may be limited, and multiple doses are likely to be required to
confer lifelong immunity or protect individuals for a long term.
1.6.2 Current progress on monoclonal antibodies
Monoclonal antibodies (mAbs) are the fastest-growing immunotherapeutics in the pharmaceutical
industry and have proved to be effective factors to treat several viral infections such as HIV, human
papillomavirus, respiratory syncytial virus, human cytomegalovirus, Ebola, Rabies, Zika, and influenza
(Salazar et al., 2017). Recent, publications have shown the ability of mAbs to neutralize SARS-CoV-2
infections (Rogers et al., 2020). Specifically, mAbs against the RBD of the subunit S1 of the spike protein
are the most promising therapeutic targets (Sternberg and Naujokat, 2020). Unlike vaccines, mAbs confer
passive immunity immediately after administration and are relatively safe (Ahangarzadeh et al., 2020).
Additionally, vaccines require a longer time to generate a protective immune response in patients, and
depending on its nature they may require additional safety evaluations (Philadelphia, 2020). Therefore,
vaccine development requires a longer evaluation process compared to antibodies. Thus, mAbs against
SARS-CoV-2 could become an alternative treatment while a vaccine is being developed and its safety is
evaluated. Besides, this is maybe the only option for individuals who may not be eligible for vaccination
such as immunocompromised individuals, neonates, the elderly, pregnant women, or individuals with
other underlying health conditions (CDC, 2020d). Despite the potential of mAbs as a treatment for
COVID-19 patients, the production of mAbs as a human therapy requires a complex pipeline of
production which often involves the immunization of transgenic rats, screening and immortalization
through hybridoma technology of a large number of clones, the engraftment of the complementaritydetermining regions (CDR) into humanized or human antibody frameworks, or reformatting of Fc regions
to the appropriate host species, such as to humans (Harding et al., 2010).
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1.6.3 Single domain antibodies
A simpler and faster way to produce therapeutic antibodies can be done by screening single
domain antibody (dAbs) libraries through phage display technology (Zhao et al., 2016). dAbs or
nanobodies are antibody fragments (12-15kDa) that contain three CDR regions within a heavy chain (VH)
framework: CDR1, CDR2, and CDR3 with CDR3 being the longest region (Belanger et al., 2019).
Because nanobodies can have an extended CDR3, they can reach hidden conformational epitopes of
complex target molecules that conventional antibodies cannot reach (Henry and MacKenzie, 2018). While
they may be ~10 times smaller than conventional antibodies, nanobodies keep all the binding properties
of full-length antibodies and have higher tissue penetration due to their smaller size (Yang and Shah,
2020). Additionally, therapeutic nanobodies can be isolated within weeks from already available human
dAb libraries using phage display technology (Lee et al., 2007). These antibody fragments can then be
easily sequenced, re-formatted, and expressed in either prokaryotic or mammalian expression systems
(Kim and Lee, 2009). In the past, human nanobodies were successfully used to neutralize SARS-CoV-1
infections (Leung et al., 2008). As SARS-CoV-2 keeps spreading and infecting individuals from multiple
geographic areas, several mutations in the viral genome have been reported including mutations in the
RBD of the spike protein. These mutations in the RBD have created at least 18 different strains of the
SARS-CoV-2 virus, some of which may have enhanced infectious capacity (Junxian Ou et al., 2020,
Isabel et al., 2020). Therefore, as the virus keeps evolving, additional antibody discovery for the
neutralization of multiple strains of the virus is required.
1.6.4 Disinfectants against SARS-CoV-2
Enhanced disinfection and other preventative measures against SARS-CoV-2 have been adopted
worldwide to limit its spread. Since SARS-CoV-2 is both a novel virus and a biosafety level-3 (BSL-3)
agent, specific disinfection data for this virus are scarce. Consequently, studies using other coronaviruses
have been used to draw conclusions about which disinfectants are most effective against it. While this
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approach is useful, it is also inherently speculative, since even viruses within the same family can respond
differently to a given disinfectant (Kahrs, 1995). Additionally, experts disagree about which disinfectants
should work best against SARS-CoV-2, especially when it comes to quaternary ammonium compounds
(quats). For instance, one prominent review article reported that benzalkonium chloride was probably
“less effective” against SARS-CoV-2, which was cited by the Centers for Disease Control (CDC) of the
United States as a reason to avoid using benzalkonium chloride-based hand sanitizer products (Kampf et
al., 2020, CDC, 2020a). At the same time, the Environmental Protection Agency (EPA) of the United
States and Health Canada both list a benzalkonium chloride product on their official list of disinfectants
recommended for use against SARS-CoV-2(GOV, 2020a). Many nosocomial outbreaks of COVID-19
have been documented to date, and hospitals need laboratory-documented techniques for effective
decontamination. More research is needed in this area to help to stem the current pandemic.
In this study, we tested 0.2% benzalkonium chloride and three commercial quat disinfectants
against SARS-CoV-2. The three commercial disinfectants we tested were Cavicide (Metrex Research
LLC, Orange, CA, USA), a widely used quat hospital disinfectant; Clean Quick Broad Range Quaternary
Sanitizer (Procter and Gamble Company, Cincinnati, OH, USA), a multi-use quat disinfectant safe for
food contact surfaces; and fluid extracted from Qimei® Hand Sanitizing Wipes, a benzalkonium chloride
household product (Zhejiang Qimei Commodity Company, Ltd., Haining City, Zhejiang, CN). Full
details for each disinfectant are included in Table 1. A suspension test method was used, and the
surviving virus was assayed using a plaque assay with Vero E6 (ATCC CRL-1586) cells. We found that
all four compounds, except for Clean Quick, effectively inactivated SARS-CoV-2 within 15 seconds of
contact and in the presence of an organic soil load. In addition, dilution of the disinfectants in hard water
had little effect on virus inactivation.
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Table 1: Disinfectant properties
Product (manufacturer

Intended use for product

Active ingredient

name)

Benzalkonium chloride

(Concentration)

Laboratory chemical

Benzalkonium chloride

Suggested contact time
(EPA List N)

N/A

(0.2%)

Qimei® Hand Sanitizing

Sanitizing hands

Benzalkonium chloride

Wipes (Zhejiang Qimei

N/A

(0.13%)

Commodity Company)

Cavicide (Metrex

Disinfecting medical

Disobutylphenoxyetho-

Research LLC)

devices, non-porous

xyethyl dimethyl benzyl

surfaces in healthcare

ammonium chloride

facilities

(0.28%), isopropanol

2 min

(17.20%)

Clean Quick (Procter & Disinfecting food contact Alkyl dimethyl benzyl
Gamble Company)

surfaces, dishes in third

ammonium chlorides

compartment sinks

(0.15%), alkyl dimethyl
ethylbenzyl ammonium
chlorides (0.15%)
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10 min

1.6.5 AIM of SARS-CoV-2 study
The principal focus of this study is to determine the inactivation capacity of different disinfectants
against SARS-CoV-2 in suspension tests at different contact times. Specifically, we are trying to show the
efficacy of quats against what was originally thought. On the other hand, we are trying to develop human
nanobodies capable of neutralizing SARS-CoV-2 strains from the US, Europe, and Asia. This study was
published in the Journal of Hospital Infection.
CHAPTER 2: Materials and methods
2.1 HIV
2.1.1 Plasmids
HIV-1 pNL4-3 was obtained through the NIH AIDS Reagent Program, Division of AIDS,
NIAID, NIH: HIV-1 NL4-3 Infectious Molecular Clone (pNL4-3) from Dr. Malcolm Martin (Cat#
114)(Cann et al., 1990, Haltiner et al., 1985, Koyanagi et al., 1987). HIV-1 NL4-3 R36W Vpr and HIV-1
NL4-3 R77Q Vpr mutants were a gift from Dr. Velpandi Ayyavoo (University of Pittsburgh). The region
surrounding the vpr gene was cloned into the pUC19 vector (Addgene #50005) using the EcoRI and SbfI
sites (New England Biolabs) for SDM. SDM was accomplished using back to back primers with single
point mismatches to change the ATG codon to GTG for the null mutant to not affect any overlapping
genes in the viral genome (Forward: CAGAGGACAGGTGGAACAAGC; Reverse:
TCAGTTTCCTAACACTAGGC). After SDM the vpr gene was removed from pUC19 using the same
enzymes and ligated back into its original frame in the pNL4-3 vector. The desired mutation and in-frame
ligations were confirmed by Sanger sequencing. One-shot Stbl3 E. coli cells (Invitrogen C737303) were
used for transformations to avoid plasmid recombination.
Additionally, Vpr mutants using the JR-CSF backbone were built for future research on human
peripheral blood mononuclear cells (PBMCs) and in humanize mice. The plasmid pYK-JRCSF was
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obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 JR-CSF
Infectious Molecular Clone (pYK-JRCSF) (Cat# 2708) from Dr. Irvin SY Chen and Dr. Yoshio Koyanagi
(Koyanagi et al., 1987, Haltiner et al., 1985, Cann et al., 1990). The region surrounding the vpr gene was
treated as described above to insert the mutations R36W, R77Q, and M1V. The sequences used to
generate the mutants were the following. For M1V, CAGAGGATAGGTGGAACAAGC forward and
TTAGTTTCTTAACACTAGGC reverse. For R77Q, ATTGGGTGTCAACATAGCAGAATAG forward
and TCTGAAATGAATAAACAGCAG reverse. For R36W, ACATTTTCCTTGGATCTGGCTC
forward and CTAACAGCTTCATTCTTAAG reverse.
Besides the projects described in the introduction, we are trying to develop a system that could
efficiently protect human PBMCs from HIV. To do so, we built a lentiviral plasmid containing a set of
gRNAs. This set, together with a Cas9 nuclease, has already shown promising results at targeting the Gag
and the Tat-Rev genes avoiding escape mutations (Wang et al., 2016).
The vector containing Cas9 that was chosen for this project was the pLentiCas9-EGFP, which
was obtained from Addgene (#63592). pLentigRNA-TatRev-Gag-RFP (figure 4) was originally the
plasmid pLenti-Guide-Puro, (Addgene 52963). It was cut in the restriction sites Mlu-I and Kfl-I (New
England Biolabs) sequences to add the following elements: RFP under the control of UBC promoter, anti
Gag1 gRNA under the control of mouse U6 promoter, and anti-Tat-Rev gRNA under the control of
human U6 promoter. The ligation was performed using the Genbuilder Cloning Kit (GenScript #L00701).
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Figure 4: Map of pLentigRNA-TatRev-Gag-RFP
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2.1.2 Cell culture
HEK293FT cells were maintained at 37ºC, 5% CO2 in DMEM (Sigma-Aldrich) supplemented
with 10% fetal bovine serum (FBS; HyClone), 2% glutamine, 1% G418 (Teknova) and 1%
penicillin/streptomycin (P/S). HUT78, CEM, and SupT1 cells were maintained at 37 ºC, 5% CO2 in
RPMI (Mediatech) supplemented with 10% FBS, 1% glutamine, and 1% P/S. Ghost R3/X4/R5 cells were
maintained at 37ºC, 5% CO2 in DMEM, supplemented with 10% FBS, 1% P/S, 500 g/mL G418, 100
g/mL hygromycin, and 1 g/mL puromycin. (Ghost cells were obtained through the NIH AIDS Reagent
Program, Division of AIDS, NIAID, NIH: GHOST (3) CCR3+ CXCR4+ CCR5+ Cells from Dr. Vineet
N. KewalRamani and Dr. Dan R. Littman (cat# 3943)(Morner et al., 1999)).
2.1.3 Virus isolate
NL4-3 HIV-1 strain was used for all the experiments. Mutations in Vpr were performed and
confirmed as explained above, in the context of the NL4-3 isolate.
2.1.4 Transfection and viral titration
HEK293FT cells were transfected using the calcium phosphate method; the virus was collected
48 hours post-transfection. Viral concentration was determined by titration using Ghost R3/X4/R5 cell
line using the methods described at the NIH AIDS Reagent Program
(http://www.aidsreagent.org/pdf_images/3685_003.pdf).
2.1.5 HIV-1 infections and flow cytometry analysis
Cells were infected with 0.1 MOI (cell cycle analysis) or 0.01 MOI (all other experiments) with
polybrene. Cells were collected on the specified day of infection for each test and prepared as follows for
Annexin V flow cytometry analysis. Cells were washed twice with serum-free PBS and centrifuged for 5
minutes at 500 x g, stained with Fixable Viability Dye (FVD) for 30 minutes at 4ºC, and then washed
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with FACS staining buffer (FCSB) (140mM NaCl, 4mM KCl, 0.75 mM MgCl2, 10mM HEPES, 1% BSA,
0.1% NaN3), CaCl2 was then added at a concentration of 1.5mM for 10min before staining with
fluorochrome-conjugated Annexin V for 15m at 25°C. Cells were then washed with FCSB and 1.5 mM
CaCl2, fixed with Solution A and 1.5 mM CaCl2 for 30 minutes, washed with FCSB, and permeabilized
with Solution B (Fix & Perm, Nordic MUbio, GAS-002). The anti-p24 antibody was then added at a final
dilution of 1:400, and cells were incubated for 15m at 25°C. Cells were then washed twice with FCSB,
resuspended, and analyzed by flow cytometry using a Beckman Coulter Cytoflex Cytometer (Purdue,
Volume 10, Trahtemberg et al., 2007). Results were analyzed using FlowJo software (version 10.6.2).
The dyes used were: KC57 anti-HIV-1 core antigen-PE (Beckman coulter CO604667), Live/Dead fixable
Far Red Dead Cell Stain Kit (Invitrogen L10120), and Annexin V Alexa 488 conjugate (Invitrogen
A13201). For cell cycle analysis we used the FxCycle PI/ RNase Staining Solution (Invitrogen F10797)
together with KC57 anti-HIV-1 core antigen-FITC (obtained through the NIH AIDS Reagent Program,
Division of AIDS, NIAID, NIH: Anti-HIV-1 p24 Monoclonal (KC57)-FITC from NIAID, DAIDS (cat#
13450)).
For TUNEL assays, cells were stained with FVD and then stained for TUNEL analysis using
FragELTM DNA Fragmentation Kit, Fluorescent-TdT Enzyme (Millipore QIA39) following the
manufacturer’s protocol.
2.1.6 Immunoblotting
At 7dpi HUT78 cells were washed with ice-cold PBS and lysed in RIPA buffer (ThermoFisher)
with protease inhibitor cocktail (ThermoFisher). Proteins were quantified using the BSA Protein Assay
Kit (ThermoFisher). Equal amounts of protein were boiled with 6X loading buffer (375mM Tris HCL,
9% SDS, 50% Glycerol, 0.03% Bromophenol blue) for 5 minutes. Samples were run through a 4-15%
gradient polyacrylamide gel and then transferred to a PVDF membrane (BioRad). The membrane was
blocked with PBS containing 5% non-fat milk for 1h at 25°C. Vpr was probed using Anti-HIV-1 Vpr
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polyclonal (diluted 1:3,000) (The following reagent was obtained through the NIH AIDS Reagent
Program, Division of AIDS, NIAID, NIH: Cat#11836, Anti-HIV-1 Vpr 1-50 aa Polyclonal from Dr.
Jeffrey Kopp). GAPDH was probed using Rabbit anti-GAPDH (diluted 1:3,000) (Cell Signaling
Technology). Both antibodies were detected using Goat anti-Rabbit HRP-conjugated (1:15,000) (Abcam
#ab6721) antibodies. Detection was done using WesternBright ECL (Advansta) and results were analyzed
using ImageJ software.
2.1.7 Viral replication
Viral supernatants were collected on days 3, 5, and 7, and viral RNA was extracted using Viral
Nucleic Acid Extraction kit II (Scientific FF10616-GB). The extracted RNA was used as a template to
produce cDNA using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems 4368814) and
LTR-specific primers. Finally, 2X Forget-Me-Not Universal Probe Master Mix with ROX (Biotium
31044-1) was used to perform Q-RT-PCR in an Applied Biosystems StepOnePlusTM Real-Time PCR
System Thermal Cycling Block, following the protocol described previously by Rouet et al (Rouet et al.,
2005). The software used to analyze the data was StepOnePlus Software 2.2.3.Ink and results were
normalized to RNA copies / mL.
2.2 SARS-CoV-2
2.2.1 Cell culture and virus production
Vero E6 (ATTC CRL-1586) cells were maintained at 37°C with 5% CO2 in Dulbecco’s Modified
Eagle Medium (Sigma), 10% Foetal Bovine Serum (HyClone), and 1% Penicillin/Streptomycin (VWR).
Virus stocks were prepared by infecting Vero E6 cells at an MOI of 0.1 and collecting the supernatant at 3
days post-infection (dpi), and the concentration of virus present was determined by plaque assay at 3 dpi.
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2.2.2 Virus isolates
All the disinfectant tests were performed using SARS-CoV-2 Isolate USA-WA1/2020 NR-52281
Additional strains used in the nanobody neutralization test include Hong Kong/VM20001061/2020 NR52282, Italy-INMI1 NR 52284, and New York-PV08410/2020, NR-53514. All samples were originally
deposited by the Centers for Disease Control and Prevention of the United States and obtained through
BEI Resources, NIAID.
2.2.3 Plaque assay
4 x 105 Vero E6 cells per well were seeded in 12-well plates a day before infection, allowing for
90-100% confluence at the time of infection. Photographs of the plaques and cell layers observed are
included in Figure 5.

Figure 5: Microscope pictures of intact cell layer and two plaques
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2.2.4 Disinfectant test and neutralization reagents
SARS-CoV-2 virus stocks with a concentration of 1 x 107 PFU/mL were used to prepare test
suspensions containing 5% bovine serum albumin (BSA) or 0.5% mucin. These were then exposed to the
disinfectants for various contact times and held at room temperature.
Neutralizer was prepared on the same day it was used, and our neutralizer recipe was adapted
from Wood et al with two substitutions (Wood and Payne, 1998). We used fetal bovine serum instead of
horse serum, and we used 0.5 M tris buffered at pH 7.5 instead of 0.25 M tris buffered at pH 7.2. For
sterilization, the neutralizer was passed through a 0.45 µm filter.
The test method was derived, with some adaptation, from ASTM protocol E1052-20, ASTM
protocol E2197-19, and AOAC protocol 960.09 (Laboratory, 2011, E1053-20, 2020, E2197-17e1, 2017).
The general form of this experiment, including the dilution scheme, neutralizer control, and bovine serum
albumin soil load, come from ASTM E1052-20. The hard water used for this experiment is 300 ppm
CaCO3, which is suggested in the ASTM E2197-19 protocol, while the recipe used to make the hard
water comes from AOAC protocol 960.09.
2.2.5 Disinfectant test
The ratio of virus inoculum to the solution was 1:10 by volume: 1 part virus per 9 parts
disinfectant. After the specified contact time, the disinfectant-virus mixtures were then diluted 1:10 into a
neutralizer solution except for the Qimei wipe liquid, which was diluted 1:20 into neutralizer to address
cytotoxicity concerns. From there, serial 1:10 dilutions of the neutralized mixtures were performed in
sterile 1x PBS, and 200 µL aliquots of the resulting solutions were added to Vero E6 cells just after the
cell culture media was removed. Plating was done in duplicate, and cells were then incubated at 37°C for
1 hour. After incubation, 1.5 mL of a low-melting top agar overlay containing 1x DMEM culture media
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and 1.5% SeaPlaque™ GTG™ agarose (Lonza, Rockland, ME USA) was added to each well, and cells
were incubated for 72 hours at 37°C to allow plaque formation.
Once plaques were established, a 10% formaldehyde solution was added for 1 hour to inactivate
any infectious virus, and top agar was removed. Cells were stained with 1% crystal violet, and plaques
were counted manually using microscopy, observing for cytopathic effects. All experiments were
performed in a BSL-3 laboratory, with approval from the Institutional Biosafety Committee at Brigham
Young University (protocol 2020-0069). Each test was repeated once on at least two different dates.
In addition to the test method, two simultaneous controls were run: a titer and a neutralizer
control. For the titer, serial 1:10 dilutions of the virus were performed in 1x PBS, and the virus was plated
as described above. For the neutralizer control, each disinfectant was diluted 1:10 in the neutralizer, and
immediately after mixing, approximately 105 PFU of the virus was added. After incubation at room
temperature for ten minutes, serial 1:10 dilutions were then performed in PBS, and plating was performed
as described above. The purpose of this control was to ensure that neither the neutralizer nor the
neutralized disinfectants were cytotoxic or virucidal and to make sure that the neutralizer effectively
stopped the activity of the disinfectant.
2.2.6 SARS-CoV-2 neutralization assay
Stocks of SARS-CoV-2 WA strain were made by infecting Vero cells and collecting the
supernatant at 3 dpi. The viral titers were determined by plaque assay on Vero cells using serial dilutions
of the collected virus. For the antibody neutralization assay, Vero cells were seeded in 24-well plates a
day before infection. Serially diluted single domain antibodies/plasma were mixed with 2000 PFU of
SARS-CoV-2 and incubated at room temperature for 1 hour. The antibody-virus mixture (or control with
no antibody added) was used to infect Vero cells at 37°C for 1 hour. Unbound SARS-CoV-2 virions were
removed by washing cells with PBS, an overlay was added, and cells were incubated for 72 hours at 37°C

36

to allow plaque formation. A 10% formaldehyde solution was added for 1 hour and then top agar was
removed. Cells were stained with crystal violet. Plaques were manually counted and cytopathic effects
were observed by microscopy.
2.3 Statistical analysis
Biological samples were analyzed in triplicate using one-tailed Student’s t-test with a significance
level of p < 0.05.
CHAPTER 3: Results and discussion
3.1 HIV
3.1.1 Construction of vpr mutants
All virus strains used in this study were based on the wild-type (WT) pNL4-3 molecular clone,
which uses CXRC4 as a co-receptor. The R36W and R77Q constructs were produced by replacing the
WT vpr gene with mutated vpr sequences from expression plasmids obtained from Dr. Velpandi Ayyavoo
(Hadi K, 2014). We created the Vpr null mutant to study the effects of HIV infection with a defective vpr
gene but without any mutations in neighboring genes/reading frames. This was accomplished using sitedirected mutagenesis (SDM) to mutate the vpr start codon (ATG to GTG, or M1V), resulting in a silent
mutation in nucleotide 173 of the overlapping vif gene (AGA to AGG; both encode arginine). Figure 6A
shows the differences in nucleotide sequences between each strain and the corresponding change in amino
acid sequence. Sanger DNA sequencing was used to confirm the desired mutations and to show that no
additional mutations were introduced during the creation of constructs (data not shown).
To confirm the expression of Vpr in WT, R36W, and R77Q mutants, and the lack of expression
in the null mutant, we detected Vpr expression via immunoblotting of infected cell lysates. Infected
HUT78 cell lysates (a human CD4+ T cell line) collected at 7dpi at MOI 0.01 were used (this time point
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was chosen because viral genome levels were most similar (see Figure 7A). HUT78 cells were derived
from a cutaneous T cell lymphoma, and represent a mature CD4+ helper T cell line that supports HIV-1
infection (Bunn and Foss, 1996). We found that the WT virus as well as the R36W and R77Q mutants
produced detectable Vpr, while no Vpr was detected in the null mutant or uninfected cells (Fig. 5B). Vpr
expression from the R77Q mutant was consistently found at reduced levels compared to the WT and
R36W.
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Figure 6: Map of Vpr mutations and immunoblot
(A) Sequence comparison of the mutations produced by site-directed mutagenesis in NL4-3 HIV vpr. (B)
Immunoblotting confirmed Vpr expression in HUT78 cells infected with WT, R36W, or R77Q while no Vpr
expression was detected in the null mutant or in uninfected cells. GAPDH was used as a loading control.
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3.1.2 The R36W mutant has an enhanced replication capacity relative to the WT virus
To examine the replicative capacity of our mutants in a T cell line, HUT78 cells infected at 0.01
MOI were analyzed for viral replication via Q-RT-PCR over 21 days post-infection. We observed
significant differences in virus replication levels amongst the various strains used within the first 7dpi, but
similar values thereafter, thus we focused our analyses on the first 7 days (Figure 7A). After 3 days, the
only statistically significant difference in genome copy number that we observed was between the R77Q
and WT populations. The R77Q infected population had a viral load of 1.0x108 RNA copies/mL, which
was almost ten-fold higher than the load of the WT virus (1.7x107 copies/mL), but at 5 and 7 days postinfection (dpi), there was no difference between these populations. The R36W-infected population had a
ten-fold higher load (2.9x109 copies/mL) that was significant compared to all other strains at 5 dpi. While
still statistically significant at 7 dpi, the difference between R36W and the other strains was considerably
smaller (Figure 7A). There was no significant difference in viral load between the WT, R77Q, and null
viruses at either 5 or 7 dpi (Table 2). Each mutant’s capacity to spread through the culture was studied by
measuring the p24 expression of individual cells through flow cytometry (Figure 7B/7C). Cells infected
with the R36W mutant showed a significantly increased p24+ population at all three-time points
compared to the WT and null viruses (Table 3). R36W also had much higher p24 expression than R77Q
at 3 and 5 dpi, but on day 7, both populations were about 80% p24+. Mean fluorescent intensity (MFI) of
p24+ histograms were also examined and showed that p24 production in individual cells was also
significantly higher following infection with the R36W mutant as compared to all other virus strains
(Table 4), indicating that viral gene expression was also higher in cells infected with the R36W mutant.
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Figure 7: The R36W mutant shows enhanced viral replication
R36W, R77Q or null HIV Vpr mutants, or WT NL4-3 were used to infect HUT78 cells at MOI 0.01. At 3, 5 and
7 dpi supernatants were analyzed for viral load and cells were analyzed for p24 expression. A) Quantification of
viral replication was determined through Q-RT-PCR. B) Assessment of p24+ populations via flow cytometry.
Histograms show representative results from 7 dpi. In B, asterisks only show statistical differences between R36W
compared to all other samples. The data are representative of 3 independent experiments and error bars indicate
Standard Error (SE). * p-value < 0.05, ** p-value < 0.01. See Table 2, 3 and 4 for complete statistical analysis.
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Table 2: Q-PCR statistical analysis from days 3, 5 and 7

T-Test
Day 3

R36W

R77Q

Null

2.50 x 106

WT

0.081

0.029

0.117

8

1.30 x 10

R36W

0.108

0.103

3.75 x 107

2.17 x 107

R77Q

2.89 x 107

1.67 x 107

Day 3

Mean

SD

SE

WT

1.71 x 107

4.33 x 106

R36W

2.97 x 10

2.25 x 10

R77Q

1.03 x 108

Null

4.23 x 107

8

8

Day 5

T-Test
Day 5

R36W

R77Q

Null

0.005

0.113

0.439

0.005

0.007

WT

1.96 x 108

1.22 x 108

7.06 x 107

WT

R36W

2.88 x 109

5.79 x 108

3.34 x 108

R36W

R77Q

2.38 x 108

1.00 x 108

5.77 x 107

R77Q

Null

108

107

107

1.81 x

8.77 x

5.06 x

Day 7

R36W

R77Q

Null

0.029

0.409

0.098

0.005

0.033

1.01 x 109

5.54 x 108

3.20 x 108

WT

R36W

1.75 x 109

5.60 x 108

3.24 x 108

R36W

R77Q

108

108

108

R77Q

Null

5.28 x 108

4.54 x

2.20 x 108

2.62 x

1.27 x 108
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0.226

T-Test
Day 7

WT

9.79 x

0.113

0.108

Table 3: p24 positive population assessment statistical analysis from days 3, 5 and 7

Day 3

Mean

SD

SE

T-Test
day 3

WT

WT

1.64

0.88

0.51

R36W

0.001

R36W

12.1

0.79

0.46

R77Q

0.026

0.001

R77Q

3.49

0.25

0.15

Null

0.166

0.001

0.005

Null

0.96

0.21

0.12

Day 5

Mean

SD

SE

T-Test
day 5

WT

R36W

R77Q

WT

10.24

0.76

0.44

R36W

0.0003

R36W

63.13

2.97

1.71

R77Q

0.0378

0.0003

R77Q

18.83

4.91

2.84

Null

0.0001

0.0003

0.0142

Null

3.7

0.58

0.34

Day 7

Mean

SD

SE

T-Test
day 7

WT

R36W

R77Q

WT

60.13

3.06

1.77

R36W

0.002

R36W

79.63

4.94

2.85

R77Q

0.014

0.353

R77Q

81.73

3.62

2.09

Null

0.028

0.007

Null

50.37

1.59

0.92
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R36W

R77Q

0.001

Table 4: p24 positive population assessment, MFI statistical analysis from days 3, 5 and 7

Day 5

Mean

SD

SE

T-Test day
5

WT

R36W

R77Q

Null

Uninfected

7410.33

1160.96

670.28

Uninfected

0.0227

0.0010

0.0209

0.4272

WT

9534.67

559.53

323.04

WT

0.0012

0.0797

0.0133

R36W

42305.67

3280.50

1894.00

R36W

0.0003

0.0011

R77Q

11785.33

2335.77

1348.56

R77Q

Null

7575.67

595.65

343.90

Day 7

Mean

SD

SE

T-Test day
7

WT

R36W

R77Q

Null

Uninfected

4585.00

506.31

292.32

Uninfected

0.0025

0.0086

0.0047

0.0005

WT

23375.67

1848.05

1066.97

WT

0.0162

0.0156

0.0334

R36W

45767.67

8974.00

5181.14

R36W

0.1564

0.0184

R77Q

59704.67

9643.82

5567.86

R77Q

Null

18397.33

695.42

401.50
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0.0368

0.0078

3.1.3 Infection with R77Q mutant leads to an increase in apoptosis
To test whether the Vpr mutants induced differing levels of apoptosis, we infected HUT78 cells at
0.01 MOI and stained with Annexin V and Fixable Viability Dye (FVD), and analyzed the results via
flow cytometry. Annexin V binds to phosphatidylserine, which flips from the inner layer of the plasma
membrane to the outer layer during the early stages of apoptosis (Fadok et al., 1992). Cells were also
stained with FVD, which enters cells through porous plasma membranes and indiscriminately binds
proteins. Since cells with a permeabilized membrane will also allow Annexin V staining due to the
antibody finding phosphatidylserine inside the plasma membrane, we considered cells positive for both
FVD and Annexin V as dead while cells positive for Annexin V only were considered to be apoptotic.
The results of this assay (Figure 8) showed a clear difference in levels of apoptotic induction by
the R77Q mutant. At all three time points, the R77Q-infected population had significantly higher levels of
apoptosis; at 7 dpi, the R77Q population had a mean level of 47.4% Annexin V single-positive cells,
compared to 2.64% in WT, 5.54% in R36W, 7.26% in null, and 3.29% in the uninfected population
(Figure 8A/8B). The only significant difference in the number of apoptotic cells in the WT and R36W
populations was 7 dpi; on days 3 and 5, the two populations had similar numbers of apoptotic cells (Table
6). The null population also had a significant increase in the number of apoptotic cells (7.26%) at 7 dpi
compared to the WT population. The null population had similar numbers of apoptotic cells to R36W at
both 3 and 7 dpi, but interestingly had a significantly (p=0.021) lower number of apoptotic cells as
compared to R36W when observed at 5 dpi (Table 6). The number of apoptotic cells in the WT
population was not significantly different from the uninfected population at all three-time points.
Additionally, we tested a different T cell line called CEM, which showed the same apoptotic phenotype
after a shorter incubation (3 days), proving that this phenotype is not only shown by HUT78 cells.
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Table 5: FVD necrosis study statistical analysis from days 3, 5 and 7

Day 3

Mean

SD

SE

T-Test
day 3

Uninfected

Uninfected

5.96

1.53

0.88

WT

0.251

WT

7.35

2.22

1.28

R36W

0.058

0.177

R36W

9.24

0.77

0.45

R77Q

0.138

0.099

0.001

R77Q

4.39

0.56

0.32

Null

0.141

0.059

0.003

0.182

Null

3.76

1.08

0.63

Day 5

Mean

SD

SE

T-Test
day 5

Uninfected

WT

R36W

R77Q

Uninfected

2.54

0.32

0.19

WT

0.0057

WT

4.66

0.32

0.19

R36W

0.0002

0.0003

R36W

16.08

0.15

0.08

R77Q

0.00002

0.0399

0.0003

R77Q

5.46

0.33

0.19

Null

0.0857

0.0128

0.0001

0.0018

Null

2.89

0.21

0.12

Day 7

Mean

SD

SE

T-Test
day 7

Uninfected

WT

R36W

R77Q

Uninfected

3.65

0.38

0.22

WT

0.0016

WT

25.35

2.41

1.39

R36W

0.0017

0.0047

R36W

44.81

4.20

2.43

R77Q

0.0001

0.0081

0.0032

R77Q

15.47

0.21

0.12

Null

0.0081

0.0104

0.0014

Null

13.39

1.92

1.11
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WT

R36W

R77Q

0.1019

Table 6: Annexin V apoptosis study statistical analysis from days 3, 5 and 7

Day 3

Mean

SD

SE

T-Test day 3

Uninfected

Uninfected

2.12

0.59

0.34

WT

0.392

WT

1.92

0.84

0.48

R36W

0.011

0.132

R36W

0.76

0.58

0.33

R77Q

0.005

0.012

0.005

R77Q

4.45

0.42

0.24

Null

0.033

0.046

0.337

0.003

Null

0.56

0.15

0.09

Day 5

Mean

SD

SE

T-Test day 5

Uninfected

WT

R36W

R77Q

Uninfected

3.10

0.79

0.46

WT

0.296

WT

2.85

0.27

0.16

R36W

0.263

0.290

R36W

2.75

0.02

0.01

R77Q

0.001

0.002

0.003

R77Q

14.50

1.47

0.85

Null

0.021

0.023

0.021

0.001

Null

1.77

0.37

0.21

Day 7

Mean

SD

SE

T-Test day 7

Uninfected

WT

R36W

R77Q

Uninfected

3.15

0.68

0.39

WT

0.1804

WT

2.79

0.24

0.14

R36W

0.0678

0.0352

R36W

6.18

1.49

0.86

R77Q

0.0003

0.0002

0.0003

R77Q

46.13

1.42

0.82

Null

0.0003

0.0037

0.3052

Null

6.94

0.73

0.42
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WT

R36W

R77Q

0.0003

We also observed clear differences in the number of dead cells in each population, as defined by
porous plasma membranes. Apoptotic cell death does not result in plasma membrane disruption, while
necrotic death pathways do show a loss of plasma membrane integrity. At 7 dpi, all four infected
populations had significantly higher numbers of dead cells than the uninfected control (Figure 8C, Table
5). The percentage of dead cells in the R36W- and WT-infected populations was significantly higher than
in the R77Q and null populations. At both 5 and 7 dpi, there was a significant difference between the
R36W and WT populations. At both time points, the number of dead cells in the R36W population was
twice as high as in the WT population (Figure 8A/8C). The percentage of dead cells in the null-infected
population was significantly smaller than the other infected populations; it had relatively similar levels of
apoptosis to the WT but fewer overall dead cells. The lack of an FVD (-), Annexin V (+) population in
our results (Figure 8A) suggests that the WT and R36W mutants either induce extremely rapid apoptosis
or that they preferentially activate a necrotic pathway to kill cells. These data suggest that the R36W and
R77Q mutants are significantly more cytopathic than the WT virus, but that they cause cell death via
different pathways relative to each other. The CEM and SUP-T1 human T cell lines were infected
similarly and analyzed for the apoptotic phenotype observed in HUT78 cells. Interestingly, neither of
these cell lines showed apoptotic induction following R77Q infection that was different than that seen
with WT, R36W, null, or uninfected cells under the same MOI at day 7 (Data not shown).
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Figure 8: R36W and R77Q Vpr mutants trigger different death pathways.
R36W, R77Q or null HIV Vpr mutants, or WT NL4-3 were used to infect HUT78 cells at MOI 0.01. Cell
samples were analyzed at 3, 5 and 7 dpi. Apoptosis was detected by Annexin V staining and fixable viability
dye (FVD) was used to detect dead cells via penetration of the dye across a porous plasma membrane. Thus, all
FVD+ cells are expected to also bind Annexin V, but not due to phosphatidylserine flipping to the outer
membrane. A) Representative dot plots from samples collected on day 7 pi. B) Apoptotic cells (positive for
Annexin V only). C) Dead cells (all cells positive for FVD). Asterisks show statistical differences between
R36W (panels C) or R77Q (panels B) and all the other samples. Data are representative of 3 independent
experiments and error bars indicate SE. * p-value < 0.05, ** p-value < 0.01. See Table 5 and 6 for complete
statistical analysis.
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3.1.4 TUNEL staining confirms that the R77Q mutant induces apoptosis
To confirm that the double-positive dead cells observed in the Annexin V staining (Figure 8A)
had not simply undergone apoptosis more rapidly, infected cells were stained for DNA fragmentation, a
classical sign of late-stage apoptosis (Fadok et al., 1992). TUNEL (terminal deoxynucleotidyl transferasedUTP nick end labeling) analysis by flow cytometry showed minimal signs of DNA fragmentation in the
uninfected, WT, R36W, and null mutant infected populations at both 5 and 7 dpi, while the R77Qinfected population had a significantly increased percentage of apoptotic cells (Figure 9A/9B, Table 7).
At 7 dpi, the R77Q-infected population was 8.34% positive for TUNEL, while all the other populations
had minimal TUNEL+ cells. Figures 9C/9D show a comparison of our apoptosis results as detected by
either Annexin V or TUNEL staining. The R77Q mutant showed a significantly higher proportion of cells
with apoptotic markers on days 5 and 7 compared to all other samples, as detected by each assay. The
percentage of R77Q-infected cells positive for Annexin V was higher than the percentage of cells positive
for TUNEL on days 5 and 7. This may be because phosphatidylserine exposure occurs earlier during the
apoptotic process than does DNA fragmentation (Fadok et al., 1992), allowing a greater number of
Annexin V-positive cells to be detected if many cells have not yet progressed to late apoptosis. Together
these data show that the R77Q mutant primarily kills cells through the induction of apoptosis, while the
WT, R36W, and null viruses cause death through different, non-apoptotic pathways.
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Figure 9: R77Q enhanced apoptosis confirmed by TUNEL stain
R36W, R77Q or null HIV Vpr mutants, or WT NL4-3 were used to infect HUT78 cells at MOI 0.01. Cell
samples were analyzed at 5 and 7 dpi. A) Representative dot plots from day 7 pi. B) Bar graph representing the
TUNEL single-positive cells of each sample. C) Bar graphs comparing apoptosis results obtained through
TUNEL and Annexin V experiments on day 5 and 7. Asterisks show statistical differences between R77Q and
all the other samples. Data are representative of 3 independent experiments and error bars indicate SE. * p-value
< 0.05, ** p-value < 0.01. See Table 7 for complete statistical analysis.
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Table 7: TUNEL stain statistical analysis from days 5 and 7

Day 5

Mean

SD

SE

T-Test day
5

WT

R36W

R77Q

Null

Uninfected

0.30

0.308

0.178

Uninfected

0.368

0.089

0.005

0.178

WT

0.21

0.171

0.099

WT

0.006

0.018

0.111

R36W

0.71

0.081

0.047

R36W

0.029

0.001

R77Q

2.27

0.660

0.381

R77Q

Null

0.07

0.035

0.020

Day 7

Mean

SD

SE

T-Test day
7

WT

R36W

R77Q

Null

Uninfected

0.0000

0.0000

0.0000

Uninfected

0.095

1.000

0.005

1.000

WT

0.0037

0.0033

0.0019

WT

0.095

0.005

0.095

R36W

0.0000

0.0000

0.0000

R36W

0.005

1.000

R77Q

8.3633

1.4551

0.8401

R77Q

Null

0.0000

0.0000

0.0000

52

0.015

0.005

3.1.5 G2 cell cycle arrest is most prominent in cells infected with the R77Q mutant
To determine if these mutants differed in their capacity to arrest cells in the G2 phase, we used
flow cytometry to observe the cell cycle progression of infected cells. HUT78 cells were infected with 0.1
MOI, then at 7 dpi cells were stained with propidium iodide and with antibodies to the p24 antigen and
analyzed through flow cytometry. p24+ populations were gated to study cell cycle arrest specifically in
infected cells. Only results from 7 dpi are reported due to a need for large numbers of p24+ cells for the
analysis. Figure 10 shows a significant mean increase in detection of cells in G2 phase in most infected
samples (WT=26.0%, p=0.01; R77Q=40.4%, p=0.01; null=26.0%, p=0.03) compared to the uninfected
control (19.2%) (Table 8). R77Q showed the highest percentage of cells arrested in G2, which was
significantly higher than the other infected samples (vs WT p=0.02, vs R36W p=0.04, vs null p=0.01).
R36W G2 arrest was lower than the WT and not significantly different than uninfected. A summary of the
raw data, including an analysis of G1 and S phase populations, is found in Table 8. These results support
studies that show that the R77Q mutant enhances cell cycle arrest and that R36W has a decreased
capacity to cause cell cycle arrest (Hadi K, 2014). An analysis was also performed of p24- cells, but there
was no significant difference between WT Vpr and the three mutants, or any infected cell samples
compared to uninfected controls (data not shown). We thus conclude that the cell cycle arrest only occurs
in infected cells, and not in bystander cells.
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Figure 10: R77Q strongly enhances G2 cell cycle arrest
R36W, R77Q or null HIV Vpr mutants, or WT NL4-3 were used to infect HUT78 cells at MOI 0.1. Cell cultures
were gated on p24+ cells for cell cycle analysis. A) Representative histograms from day 7 pi. B) Percentage of
p24+ cells in G2 phase. The asterisk shows a statistical difference between R77Q and all other samples. Data
are representative of 3 independent experiments and error bars indicate SE. * p-value < 0.05. See Table 8 for
complete statistical analysis.
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Table 8: G2 cell cycle arrest statistical analysis from day 7

G2 Day 7

Mean

SD

SE

T-Test

WT

R36W

R77Q

Null

Uninfected

19.2

2.34

1.35

Uninfected

0.01

0.06

0.01

0.03

WT

26.0

1.31

0.75

WT

0.23

0.02

0.49

R36W

24.1

3.35

1.93

R36W

0.04

0.32

R77Q

40.4

5.51

3.18

R77Q

Null

26.03

3.79

2.19
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0.01

Table 9: Cell cycle arrest statistical analysis of cells in the various populations
G2
Mean

SD

SE

G2

WT

R36W

R77Q

Null

Uninfected

19.20

2.34

1.35

Uninfected

0.01

0.06

0.01

0.03

WT

25.97

1.31

0.75

WT

0.23

0.02

0.49

R36W

24.07

3.35

1.93

R36W

0.04

0.32

R77Q

40.37

5.51

3.18

R77Q

Null

26.03

3.79

2.19

0.01

G1
Mean

Mean

SD

SE

G1

WT

R36W

R77Q

Null

Uninfected

68.33

1.76

1.02

Uninfected

0.00

0.00

0.00

0.01

WT

23.43

3.33

1.92

WT

0.05

0.01

0.01

R36W

18.10

0.20

0.12

R36W

0.35

0.01

R77Q

18.97

3.53

2.04

R77Q

Null

39.73

6.18

3.57

0.01

S Phase
Mean

Mean

SD

SE

S

WT

R36W

R77Q

Null

Uninfected

29.67

0.86

0.50

Uninfected

0.01

0.03

0.07

0.00

WT

44.63

3.36

1.94

WT

0.28

0.01

0.06

R36W

46.07

5.78

3.34

R36W

0.01

0.08

R77Q

35.07

3.01

1.74

R77Q

Null

37.03

1.55

0.90
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0.26

3.1.6 Discussion
In our efforts to study the phenotypes of the R36W and R77Q Vpr mutants to gain a better
understanding of the role that HIV Vpr plays in the death of helper T cells we have made four main
conclusions: 1) The R36W Vpr mutation enhances the replicative capacity of HIV in HUT78 cells; 2) The
R77Q Vpr mutation enhances the pro-apoptotic activity of HIV; 3) The WT, R36W and null viruses kill
host cells via a necrotic, non-apoptotic pathway; and 4) The R77Q Vpr mutation enhances G2 cell cycle
arrest.
We noticed several interesting differences in apoptosis induction and cell cycle arrest with the
R77Q mutant as compared to the WT virus or the R36W and Vpr null mutants. We also detected a very
noticeable reduction in the detection of Vpr protein in R77Q-infected samples as compared to WT and
R36W viruses by immunoblotting (Figure 6B). This decreased level of Vpr from the R77Q virus was
consistently detected with different MOI, and should not be due to a change in antibody interaction
because the polyclonal antibody used was generated against the first 50 amino acids of Vpr. Thus, we
wondered if the apoptotic and cell cycle arrest phenotypes could be explained by a simple lack of Vpr
expression. However, our use of the Vpr null mutant, which never showed detectable Vpr expression by
immunoblotting (Figure 6B), failed to show either the apoptotic or the cell cycle arrest phenotypes. We
increased the MOI of Vpr null infections to see if the apoptotic phenotype could be detected under
varying experimental conditions, but increased apoptosis was never seen with that mutant. Thus,
decreased Vpr expression alone cannot explain the correlation between low or non-existent Vpr
expression and the phenotypes observed. It is possible that low levels of Vpr expression give a different
phenotype as compared to high expression or complete lack of expression; our experiments did not
address this possibility.
We examined two other human T cell lines (CEM and SUP-T1) for the apoptotic phenotype by
Annexin V and FVD staining, but we failed to observe any increase in apoptosis upon infecting these
57

other cell lines with the R77Q mutant. While the meaning of these findings is still unclear, it suggests
that something in the genotype of HUT78 cells may be different as compared to the other cell lines. This
finding is not entirely unexpected, since host genetics plus viral genetics are both thought to play a role in
AIDS progression. Future analysis of genes present or absent in HUT78 vs CEM and SUP-T1 cells, or an
analysis of gene expression profiles of the two cell types, may shed additional light on this area.
In our analysis of replication capacity by Q-RT-PCR of viral load and measurement of p24
expression via flow cytometry, we found that R36W-infected cells produced significantly more virus, and
more p24+ cells compared to other strains. Interestingly, our findings show that both the R77Q and the
null mutants behaved very similarly to the WT virus in terms of viral replication rates, suggesting that
these mutations do not impact viral replication efficiency in an in vitro setting. The mechanism by which
the R36W mutant replicates more effectively in helper T cells is still to be determined. However, our
findings have implications for the RP phenotype in that the R36W virus replicates better and spreads to
new cells more effectively than the WT virus, which would be expected for a virus associated with faster
than normal AIDS progression.
There was not a significant increase in the number of viral genome copies or p24+ cells in the
R36W-infected population from days 5 to 7. This may be because the R36W-infected population had
reached a plateau in terms of both HIV production and cell infection due to the limited number of
infectable cells in the culture. As a result, the differences in the replication kinetics of each mutant were
most visible at 5 dpi, and by 7 dpi the other mutants produced a more similar viral load. Overall, these
results show that R36W has a significantly higher replication and infection capacity compared to the WT
virus. A previous study by Hadi et al. reported that the WT virus showed the highest replication levels,
followed by R36W (among other mutants studied) and that the R77Q mutant replicated at levels sevenfold lower than the WT virus (Hadi K, 2014). However, Hadi et al. constructed their mutants using a
modified strain of HIV-1 NL4-3 engineered to express the EGFP reporter that places Nef expression
under the control of an IRES element, which could result in virus attenuation (Venkatachari et al., 2007).
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Therefore, cells infected with that virus strain may show different behavior than that observed with
normal Nef expression from unmanipulated HIV-1 NL4-3. Much of the controversy regarding Vpr
function is likely a result of the many different experimental systems used to study its effects including
primary cells, cells in a three-dimensional lymphoid tissue, and cell lines. The Hadi et al study was
conducted in primary cells, which could potentially vary inactivation status and influence the replication
kinetics of the different viruses. Our use of a clonal population eliminates this variable.
The R77Q mutant showed significantly higher levels of G2 cell cycle arrest compared to the WT
virus and the other two mutants. Since the LTR promoter is known to be most active during the G2 phase
(Thierry et al., 2004), but the R36W mutant was the strain that replicated the best, these results appear to
be conflicting. Our p24 MFI results showed the highest levels of p24 expression levels at day 7 for R77Q
(significantly different than WT, p=0.02, and Null, p=0.008), but not significantly different than R36W,
p=0.16; See Table 4), which may support the enhancement of viral gene expression due to LTR
activation. Our viral load and p24 expression results show that the R36W virus still replicates
significantly better in HUT78 cells, suggesting that the R36W mutation provides a stronger effect on viral
replication than the G2 arrest observed in R77Q infections.
A potential difference in these mutants that could affect cell killing rates is their distinct
mechanisms of causing cell death. Contrary to the results of previous studies (Andersen et al., 2006, Lum
JJ, 2003), we observed much higher rates of apoptosis in the R77Q-infected population as compared to
either the WT or the other mutant populations. The difference between our observed R77Q apoptosis
phenotype and those previously reported is also likely a result of different experimental systems. The
previous data that associated R77Q Vpr with a normal or decreased capacity for apoptosis was observed
in HeLa cells transduced with R77Q Vpr-expressing plasmids (Andersen et al., 2006) or in Jurkat cells
infected with VSV-G pseudotyped virus (Lum JJ, 2003). Our experimental system most closely resembles
the natural conditions of infection since we have studied Vpr function in the context of replicationcompetent HIV, including the apoptotic functions previously ascribed to vif, env, etc. (Selliah and Finkel,
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2001, Perfettini et al., 2005). As a cancer cell line, HUT78 cells are relatively resistant to apoptosis; this
resistance is a result of null mutations in the p53 gene (Bunn and Foss, 1996, Netchiporouk et al., 2017).
However, since Vpr-induced apoptosis is p53-independent (Stewart et al., 1999, Andersen et al., 2005),
we believe that R77Q Vpr is a bona fide pro-apoptotic mutation while WT and R36W Vpr induce
necrotic cell death.
HIV and Vpr have been shown to induce pyroptosis in bystander cells (Doitsh et al., 2014), but
this process is mediated by cell-to-cell contact (Galloway et al., 2015), primarily within three-dimensional
lymphoid tissue models and not in peripheral blood cells (Munoz-Arias et al., 2015, Trinite et al., 2016).
Therefore, it is unlikely that the form of necrotic cell death observed in our suspension of T cells was
pyroptosis (Bunn and Foss, 1996). An apoptosis-independent form of HIV-1-mediated cell death has been
previously reported (Lenardo et al., 2002, Bolton et al., 2002). More recently, necroptosis, a form of
programmed necrotic cell death was shown to take place in HIV-1 infected cells by Pan et al. (Pan et al.,
2014). Due to similarities between our data and the data reported by Pan et al., we believe that the
necrotic cell death observed in the WT, R36W, and Null populations was likely a result of necroptosis.
The mechanism by which HIV-1 induces necroptosis is still unknown, but it may be via a combination of
host and viral factors and not directly induced by a specific viral protein (Pan et al., 2014). It is interesting
to note however, that Pan et al. reported an inverse relationship between the levels of apoptosis and
necroptosis in infected populations of cells, suggesting that the pathways serve as alternatives to one
another. Mutations like R77Q that lead to a preference of one pathway over another could have a
significant impact on host-virus interactions.
3.1.7 Conclusion
In vivo, a tendency to induce pro-inflammatory death could potentially lead to a faster and/or
more potent chronic activation of the immune system, which has been hypothesized to lead to AIDS
progression (Paiardini and Muller-Trutwin, 2013). Thus, the R36W mutation could show an RP
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phenotype based upon the avoidance of apoptosis and reliance on necrotic death mechanisms, which are
highly inflammatory (Rock and Kono, 2008). This mechanism would fit in well with the RP phenotype
reported by others (Hadi K, 2014). On the other hand, it is known that apoptosis does not enhance a
systemic inflammation (Yang et al., 2015) and therefore could delay the chronic activation of the immune
system that leads to AIDS. If the R77Q mutation influences host cells to die primarily by apoptosis, this
could potentially explain the LTNP phenotype associated with it. Although R77Q is highly cytotoxic and
replicates at a similar rate to the WT virus, the death pathway followed by infected cells could
significantly alter the host’s immune response during chronic HIV-1 infection. Only an in vivo study,
however, will be able to conclusively determine the progression phenotypes of the R36W and R77Q
mutations in a more physiological setting.
In summary, we present novel replication and cytopathic phenotypes associated with the R36W
and R77Q Vpr mutations that could potentially contribute to the overall role that HIV Vpr plays in CD4+
T cell depletion.
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3.2 SARS-CoV-2
3.2.1 Background and principles of disinfectant tests
To our knowledge, only two studies have been conducted on quats and SARS-CoV-2 disinfection
so far. Chin et al tested 0.1% benzalkonium chloride against SARS-CoV-2 with no soil load, which was
effective after a 5 minute contact time (Chin et al., 2020). Ijaz et al went further, testing a 0.19% alkyl
dimethyl benzyl ammonium chloride disinfectant with a 5% FBS soil load, which was effective after a
contact time of 2 minutes (Ijaz et al., 2020). Both studies used TCID-50 assays.
This study is more precise and realistic than previous studies, adding meaningful information to
our understanding of SARS-CoV-2 disinfection. One unique aspect of this study was the use of plaque
assays to quantify viable SARS-CoV-2 virus. As a result, the number of infectious virus particles was
determined, allowing precise log reductions to be calculated, something not possible when using a TCID50 or genome copy number assay. Other unique features of these experiments include the relatively short
contact times tested (15 seconds and 30 seconds) and the organic and inorganic loads tested, including
mucin, BSA, and hard water. These variables were designed to simulate real-world conditions: in
practice, surfaces contaminated with SARS-CoV-2 is likely also contaminated with mucus or other
organic material, and water used to dilute disinfectants may contain hard water ions. In addition, most
users of surface disinfectants do not leave them on surfaces for very long. Quat compounds, in particular,
are known to vary in activity with changes in disinfectant formulation or soil load, so accounting for those
factors in laboratory tests is especially important (Kahrs, 1995). All the results are listed in Tables 10 and
11.
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Table 10: Logarithmic reduction in virus titer
Product

Concentration Exposure time

Reduction in virus titter (PFUs/mL, log 10)

No soil load 0.5% Mucin 5% BSA

Product
diluted in
hard water

Benzalkonium

0.2%

15 sec

>2.89*

>2.67*

2.09

>2.89*

30 sec

>2.72*

>2.49*

>2.49*

>2.71*

15 sec

>2.67*

>2.34*

>2.34*

N/A

30 sec

>2.47*

>2.34*

>2.34*

N/A

15 sec

>2.89*

>2.67*

>2.67*

N/A

30 sec

>2.58*

>2.67*

>2.67*

N/A

15 sec

1.53

0.31

0.00

0.45

30 sec

>2.58*

0.57

0.42

1.85

Chloride

Qimei Wipes

Cavicide

Clean Quick

Undilute

Undilute

200 PPM

For these tests, the amount of kill detected was the maximum possible to detect using the test method. N/A:
These products were not tested with hard water because they are sold in use-dilution form; they do not require
diluting to be used.
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Table 11: Disinfectant kill percentage
Product

Concentration Exposure time

Percent kill (PFUs/mL)

No soil load 0.5% Mucin 5% BSA

Product
diluted in
hard water

Benzalkonium
Chloride

Qimei Wipes

Cavicide

Clean Quick

0.2%

Undilute

Undilute

200 PPM

15 sec

>99.9

>99.8

99.2

>99.9

30 sec

>99.8

>99.7

>99.7

>99.8

15 sec

>99.8

>99.5

>99.5

N/A

30 sec

>99.7

>99.5

>99.5

N/A

15 sec

>99.9

>99.8

>99.8

N/A

30 sec

>99.7

>99.8

>99.8

N/A

15 sec

97.0

51.0

0.0

64.5
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3.2.2 Disinfection test
Each of the compounds except Clean Quick was highly effective at inactivating SARS-CoV-2,
even after only 15 seconds of contact time and in the presence of mucin or BSA soil load. Clean Quick
was effective after 30 seconds of contact time in the absence of a soil load, which matches its intended
use. The manufacturer’s website states that Clean Quick is supposed to be used as either a “non-rinse
sanitizer for third-sink sanitizing of dishes” or a sanitizer for pre-cleaned surfaces, either way with a
contact time of at least 1 minute. Under those conditions, it is likely to be effective against SARS-CoV-2
(Quick®, 2020).
3.2.3 Discussion
These results show that quats are effective at inactivating SARS-CoV-2. Interestingly, for most of
them, a low protein concentration of BSA or mucin did not affect its neutralization capacity. These results
are very promising regarding the effectiveness of a disinfectant. However, suspension tests are not
definitive regarding the neutralizing capacity of quats. To get definitive results, a disinfectant should be
tested on carrier tests, in which the virus is dried on a carrier and then disinfectant is applied. The capacity
of disinfectant to reach all the inner dried virus and inactivate it is essential to prove its efficacy as a
disinfectant to be used both as hand sanitizers or as a surface cleaner.
Quats are already the most widely represented class of disinfectants on EPA’s List N, the
agency’s official list of disinfectants recommended for use against SARS-CoV-2 based on prior studies
with other viruses (GOV, 2020a). Additionally, in July 2020, the EPA officially approved SARS-CoV-2
efficacy claims for 13 disinfectants based on laboratory testing with SARS-CoV-2 itself, and all of those
disinfectants list quats as their only active ingredients (GOV, 2020a, GOV, 2020b). Quats can be an
effective tool for helping food establishments, hospitals, and the general public to control SARS-CoV-2.
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3.2.4 Conclusion
The most significant finding of this study is that benzalkonium chloride hand sanitizer is effective
at inactivating SARS-CoV-2, which is useful for healthcare professionals to know. Since alcohol hand
sanitizer is the only type recommended by the CDC and also the only type given expedited manufacturing
approval by the U.S. Food and Drug administration, alcohol hand sanitizer has overwhelmingly been the
dominant choice for SARS-CoV-2 control in the U.S., leading to acute supply shortages in the U.S. and
elsewhere (CDC, 2020a, FDA, 2020). However, benzalkonium chloride has several advantages over
alcohol for hand disinfection: it is non-flammable, non-toxic, and less irritating to the skin (Bondurant et
al., 2020). Switching from alcohol to benzalkonium chloride hand sanitizer can lead to better hand
hygiene compliance from healthcare workers, possibly decreasing overall microbial contamination on
their hands (Bondurant et al., 2020). In conclusion, quats are effective disinfectants for the inactivation of
SARS-CoV-2. Benzalkonium chloride hand sanitizer products could be used as effective alternatives to
alcohol-based products, which may help reduce supply shortages and contribute to the containment of
COVID-19.
CHAPTER 4: Future directions
HIV: Many questions arise after our apoptosis/necrosis study performed in HUT78 cells,
probably the most interesting one is, what factors cause a different timing in the cell death phenotype in
the T cell lines? To answer this question a genome BLAST of HUT78 and CEM could be performed to
understand the genomic differences between these cell types. If the genes that are responsible for the
apoptotic phenotype were found, this knowledge could lead to a better understanding of the pathogenesis
and disease progression that is directly related to genomic variations in patients. Additionally, it could be
useful to understand up to what degree patients' genome affect disease progression and the appearance of
RP or LTNP patients.
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Another question that we were unable to answer was why immunoblotting always showed a
lower concentration of R77Q Vpr protein. We suspect that this protein may be being secreted from cells,
thus it would be hard to find in cell pellets. However, after testing supernatants, we were not able to find
the protein. It is possible that larger volumes of supernatant needed to be concentrated to be able to detect
the protein, since we use the native state of Vpr, without any kind of tags. However, it is also possible that
the Vpr containing the R77Q mutation is less stable than WT Vpr, this is also something to be considered
and that would need further research to be confirmed.
Although we have clearly established the phenotype that develops in HUT78 cells, we have not
revealed the cellular mechanisms that lead to it. To do so, both caspase activation and the production of
interleukins (IL) related to cell death could be studied. Thus, a better understanding of how R77Q Vpr
causes apoptosis would be provided.
On the other hand, both PBMC’s and humanized mice could be infected with our HIV Vpr
mutants to study the pathogenesis and progression to AIDS that is developed in each case. We foresee
that we may not find the same phenotype found in HUT78, but if we were able to determine which
mutations are needed in the host cells to achieve such a phenotype, we could either search for those
mutations in primary cells sold by companies or use the CRISPR/Cas9 technology to get stem cells
modified the way we need before the engraftment of mice.
SARS-CoV-2 non-alcoholic disinfectants: After our study, it is clear that quaternary ammonium
compounds are effective at killing SARS-CoV-2 in suspension. Our results showed the maximum
possible neutralization possible, which was about 3 logs reduction or a 99.9% of neutralizing. However,
products approved by the FDA to be used as disinfectants usually require at least 4 log reduction or
99.99% of neutralization to be approved. Additionally, they require carrier tests in which the virus is dried
on a surface in which is then applied to the disinfectant. This mix needs to be neutralized after a few
seconds and plaque assay is performed to determine the log reduction after a specific contact time.
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Nevertheless, this would be something that specific companies would be more interested in researching
and should provide the funding to carry out these experiments.
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APPENDIX
I published two review papers during my Ph.D. related to the use of nucleases in genome therapy.
The first one titled “TALEN gene editing takes aim on HIV”, was done in collaboration with the
University of Nevada. The second titled “Advances in Nucleases used for Genome Editing”, was
completely develop inside of the Microbiology and Molecular Biology Department of BYU.
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